

# Supplemental Material

**Supplemental Figure 1:** Renal biopsy findings in individuals with SRNS in whom the causative mutation was identified in 21 SRNS-causing genes (27 examined) in 615 affected individuals from 526 families.

**Supplemental Figure 2.** Distribution for age of onset of NS in 102 individuals with homozygous mutations in *NPHS2*.

**Supplemental Figure 3.** Distribution for age of onset of NS in individuals with compound heterozygous mutations in *NPHS2*.

**Supplemental Figure 4.** Distribution for age of onset of SRNS in 84 individuals with homozygous mutations in *NPHS1*.

**Supplemental Figure 5.** Distribution for age of onset of SRNS in 16 individuals with homozygous mutations in *LAMB2*.

**Supplemental Figure 6.** Percentage of genetic findings in SRNS families from the 8 largest contributing centers.

**Supplemental Figure 7.** Most frequent 18 SRNS-causing alleles in 125 families from the 8 largest contributing centers.


**Supplemental Table 1:** Characteristics of an international cohort of 1,783 families with 2,016 affected individuals.

**Supplemental Table 2.** Twenty six SRNS-causing genes that were investigated using microfluidic multiplex PCR and NGS.

**Supplemental Table 3.** Genotypes and phenotypes of mutations in 14 recessive SRNS-causing genes (*NPHS2*, *NPHS1*, *PLCE1*, *SMARCAL1*, *COQ2*, *COQ6*, *DGKE*, *MYO1E*, *LAMB2*, *CUBN*, *ITGA3*, *ITGB4*, *CFH* and *PDSS2*) detected by Sanger sequencing and high-throughput sequencing in 264 out of 1,783 families with SRNS.

**Supplemental Table 4.** Genotypes and phenotypes of mutations in *WT1* detected by Sanger sequencing and high-throughput sequencing in 35 out of 1,783 families with SRNS.

**Supplemental Table 5.** Genotypes and phenotypes of mutations in *TRPC6*, *ARHGAP24* and *INF2* detected by Sanger sequencing and high- throughput sequencing in 17 out of 1,783 families with SRNS.




Supplemental Figure 1


**Supplemental Figure 1: Renal biopsy findings in individuals with SRNS in whom the causative mutation was identified in 21 SRNS-causing genes (27 examined) in 615 affected individuals from 526 families.**

**(A)** In 337 of the displayed 544 individuals a renal biopsy was performed. Renal biopsy findings are represented by age groups. Note that renal biopsy was less frequently performed in infants and that the developmental phenotype of DMS is more frequent in infants. Not shown are 14 patients with an age of onset later than 25 years, 30 individuals, in whom no age of onset of proteinuria was available, and 27 patients with inconclusive biopsy results or Wilms tumor. **(B)** Renal biopsy findings by gene in 350 of 582 individuals with identified mutation. 20 patients with an inconclusive biopsy result and 7 patients with Wilms tumor are not included, as well as 6 individuals with disease-causing mutations in the genes *ARHGDIA*, *ARHGAP24*, *CUBN*, *CFH* and *ITGB4*, in whom two or less individuals with biopsy result were available for each gene.

## NPHS2 homozygous mutations (n= 102 individuals)




**Supplemental Figure 2. Distribution for age of onset of NS in 102 individuals with homozygous mutations in *NPHS2*.** Homozygous *NPHS2* mutations are shown for 36 different alleles. The x-axis indicates the mutations sorted by median age of onset. The y-axis indicates the age of onset of SRNS. The median age of onset was significantly different between the European founder mutation Arg138Gln (17 months) versus Leu312Val (96 months,  $p<0.05$ ), or Arg138Gln (17 months) versus Val180Met (97.5 months,  $p<0.05$ ). Symbols are colored red, green, or blue if the allele is truncating, splice or missense, respectively. Numbers with arrows represent two outliers for age of onset. Blue dotted line reflects the median age of onset for the European founder mutation Arg138Gln.  $p$  values are from two-tailed Student's t-test; mo=months.




**Supplemental Figure 3. Distribution for age of onset of NS in individuals with compound heterozygous mutations in *NPHS2*.** Forty-six individuals had compound heterozygous *NPHS2* mutations represented by 17 different alleles. Since the severity of phenotype (age of onset) of individuals with compound heterozygous mutations is decided by the “milder” mutation, the ‘X-axis’ descriptor shows first the allele thought to cause later onset (before “/”) and the second the allele thought to cause earlier onset (after “/”) as derived from data with homozygous mutations (**Appendix Figure 2**). The mutations were sorted from left to right by increasing median age of onset. For early onset (<4 yrs) the data was grouped as “Combined-Group A”. For late onset (>4 yrs) the data was grouped as “Combined-Group B”. For group A (n = 19), median age of onset was 17 months (dotted line) and for group B (n = 27), median was 138 months (dashed line). Age of onset was statistically significant between the two groups ( $p < 0.0001$ ). P values are from two-tailed student’s t-test. Symbols are colored red, green, or blue if the severity-deciding allele is truncating, splice, or missense, respectively. The European founder mutation Arg138Gln is underlined, it occurs more frequently (four of five times) in the early onset group A. The allele Arg229Gln is double underlined. It occurs more frequently (eight of 11 times) in the group with later onset (group B). Arg229Gln occurs with second alleles that were recently described to be compatible with causing SRNS in combination with Arg229Gln.

## **NPHS1 homozygous mutations (n= 84 individuals)**




**Supplemental Figure 4. Distribution for age of onset of SRNS in 82 individuals with homozygous mutations in *NPHS1*.** Homozygous *NPHS1* mutations are shown for 46 different alleles. The x-axis indicates the mutations sorted by median age of onset. The y-axis indicates the age of onset of SRNS. Symbols are colored red, green, or blue if the allele is truncating, splice, delins or missense, respectively. Numbers with arrows represent eight outliers for age of onset. Note that for 76% (35/46) of homozygous *NPHS1* mutations there was congenital nephrotic syndrome, i.e. age of onset <3 month; mo= months.

## *LAMB2* homozygous mutations (n= 16 individuals)




**Supplemental Figure 5. Distribution for age of onset of SRNS in 16 individuals with homozygous mutations in *LAMB2*.** Homozygous *LAMB2* mutations are shown for 14 different alleles. The x-axis indicates the mutations sorted by the median age of onset. The y-axis indicates the age of onset of SRNS. Symbols are colored red, green, or blue if the allele is truncating, splice, or missense, respectively. The number with arrows represents one outlier (Ser80Arg, age of onset 60 months). Note that all individuals with homozygous N-terminal truncating mutations and the one delins mutation (Cys484\*, Phe393del, Glu85Lysfs\*27) manifest before two month of life (dashed horizontal line), whereas all three individuals with homozygous C-terminal truncating mutations (Glu1528Glyfs\*2, Gln1513\*, and Arg1719Argfs\*19) manifest after  $\geq$  two months of life; mo= months.



**Supplemental Figure 6. Percentage of genetic findings in SRNS families from the 8 largest contributing centers.** We obtained samples from 1,783 SRNS families worldwide and detected the disease-causing mutation in 526 families (29.5%). For 8 centers we detected the disease causing mutations in the following fractions: (families, in whom we detected the causative mutation/total families examined from this center): Saudi-Arabia (45.2%, 28/62), Egypt (45.2%, 66/146), Turkey (37.3%, 62/169), Germany (26.9%, 123/457), Switzerland (22.1 %, 21/94), India (19.7%, 25/127,), Ann Arbor (14.3%, 8/56), and Los Angeles (13.7%, 7/51).

Inset: The detection rate of the disease-causing mutations strongly correlates with the rate of consanguinity between the different centers ( $R^2=0.9414$ ).



**Supplemental Figure 7. Most frequent 18 SRNS-causing alleles in 126 families from the 8 largest contributing centers.** In the 8 largest centers the causative mutation was detected in 559 families for a recessive gene. Pie chart segment represent percent frequency for alleles per center if allele was detected  $\geq 5$  times in the 8 centers (n=126 families and 224 alleles). We detected the different founders alleles with the following frequencies (allele detected per center/total alleles in this center): The European founder NPHS2: Arg138Gln in Germany (22.2%, 43/194), Switzerland (20%, 6/30) and Ann Arbor (22.2 %, 2/9); the Turkish founder NPHS2: Pro118Leu in Turkey (13.7%, 14/102), Germany (1.5%, 3/194); the Egyptian founders NPHS2: Met1? in Egypt (12%, 14/116) and NPHS2: Asn199Lysfs\*14 in Egypt (4.3%, 5/116); the North African founder NPHS2: Val180Met in Saudi Arabia (11.5%, 6/52) and the Indian founder NPHS1: Arg367Cys in India (15.2 %, 14/116). The most prominent allele are called out in the map, for the less prominent alleles see color legend.

**Supplemental Table 1: Characteristics of an international cohort of 1,783 families with 2,016 affected individuals.**

Gender (n= 2,016 individuals)				Parental Consanguinity ( n= 1,783 families)				Age of onset (n= 2,016 individuals) [months]	
	male	female	No Data	Total	Yes	No	No Data	Total	Median (range)
All individuals	1,067 (52.9%)	932 (46.2%)	17 (0.8%)	2,016	372 (20.9%)	1,308 (73.4%)	103 (5.7%)	1,783	41 (0- 756)
No detection of the disease causing-gene	776 (55.0%)	623 (44.2%)	12 (0.8%)	1,411	188 (15.0%)	981 (78.0%)	88 (7.0%)	1,257	53 (0- 756)
Causative gene detected	301 (48.9%)	309 (50.3%)	5 (0.8%)	615	184 (35.0%)	327 (62.2%)	15 (2.9%)	526	18 (0- 720)
Dominant	49 (41.2%)	70 (58.8%)	0 (0%)	119	7 (6.5%)	98 (91.6%)	2 (1.9%)	107	38 (0- 444)
Recessive	251 (50.7%)	239 (48.3%)	5 (1.0%)	495	177 (42.2%)	229 (54.6%)	13 (3.2%)	419	12 (0- 720)

**Supplemental Table 2. Twenty six SRNS-causing genes that were investigated using microfluidic multiplex PCR and NGS.**

Gene	Protein	Accession #	Chro- mo- some	Total Exon count	Coding exon count	Amplicon count	Amino acid conservation to species	First publication
<b><u>Autosomal recessive</u></b>								
<i>ADCK4</i>	AarF domain containing kinase 4	NM_024876.3	19	15	14	14	<i>S. cerevisiae</i>	1
<i>ARHGDIA</i>	Rho GDP dissociation inhibitor (GDI) alpha	NM_001185078.1	17	6	5	6	<i>C. elegans</i>	2
<i>CD2AP</i>	CD2-associated protein	NM_012120.2	6	18	18	18	<i>C. elegans</i>	3
<i>CFH</i>	Complement factor H	NM_000186.3	1	22	22	25	<i>D. rerio</i>	4
<i>COQ2</i>	Coenzyme Q2 4-hydroxybenzoate polyprenyltransferase	NM_015697.7	4	7	7	9	<i>C. elegans</i>	5
<i>COQ6</i>	Coenzyme Q6 monooxygenase	NM_182476.2	14	12	12	12	<i>C. elegans</i>	6
<i>CUBN</i>	Cubilin (intrinsic factor-cobalamin receptor)	NM_001081.3	10	67	67	73	<i>C. elegans</i>	7
<i>DGKE</i>	Diacylglycerol kinase, epsilon	NM_003647.2	17	12	11	17	<i>D. rerio</i>	8
<i>ITGA3</i>	Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)	NM_005501.2	17	25	25	26	<i>D. rerio</i>	9
<i>ITGB4</i>	Integrin, beta 4	NM_000213.3	17	40	39	47	<i>C. elegans</i>	10
<i>LAMB2</i>	Laminin, β2	NM_002292.3	3	32	32	35	<i>C. elegans</i>	11
<i>MEFV</i>	Pyrin	NM_000243.2	16	10	10	17	<i>M. musculus</i>	12
<i>MYO1E</i>	Homo sapiens myosin IE (MYO1E)	NM_004998.3	15	28	28	28	<i>C. elegans</i>	13
<i>NEIL1</i>	Nei endonuclease VIII-like 1	NM_001256552.1	15	10	10	10	<i>D. rerio</i>	14
<i>NPHS1</i>	Nephrin	NM_004646.3	19	29	29	28	<i>C. elegans</i>	15
<i>NPHS2</i>	Podocin	NM_014625.2	1	8	8	10	<i>C. elegans</i>	16
<i>PDSS2</i>	Prenyl (decaprenyl) diphosphate synthase, subunit 2	NM_020381.3	6	8	8	10	<i>D. melanogaster</i>	17
<i>PLCE1</i>	Phospholipase C, epsilon 1	NM_016341.3	10	33	31	46	<i>C. elegans</i>	18
<i>PTPRO</i>	Protein tyrosine phosphatase, receptor type, O	NM_030667.2	12	27	26	28	<i>D. rerio</i>	19
<i>SCARB2</i>	Scavenger receptor class B, member 2	NM_005506.3	4	12	12	12	<i>C. elegans</i>	20
<i>SMARCAL1</i>	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a-like 1	NM_014140.3	2	18	16	20	<i>C. elegans</i>	21
<b><u>Autosomal dominant</u></b>								
<i>ACTN4</i>	Actinin, alpha 4	NM_004924.4	19	21	21	21	<i>C. elegans</i>	22
<i>ARHGAP24</i>	Rho GTPase activating protein 24	NM_001025616.2	4	10	9	19	<i>D. rerio</i>	23
<i>INF2</i>	Inverted formin, FH2 and WH2 domain containing	NM_022489.3	14	23	21	28	<i>D. rerio</i>	24
<i>LMX1B</i>	Homo sapiens LIM homeobox transcription factor 1, beta (LMX1B)	NM_001174147.1	9	8	8	9	<i>C. elegans</i>	25
<i>TRPC6</i>	Transient receptor potential cation channel, subfamily C, member 6	NM_004621.5	11	13	13	20	<i>D. rerio</i>	26
<i>WT1</i>	Wilms tumor 1	NM_024426.4	11	10	10	13	<i>S. cerevisiae</i>	27

**Supplemental Table 3. Genotypes and phenotypes of mutations in 14 recessive SRNS-causing genes (*NPHS2*, *NPHS1*, *PLCE1*, *SMARCAL1*, *COQ2*, *COQ6*, *DGKE*, *MYO1E*, *LAMB2*, *CUBN*, *ITGA3*, *ITGB4*, *CFH* and *PDSS2*) detected by Sanger sequencing and high-throughput sequencing in 280 out of 1,783 families with SRNS.<sup>#</sup>**

Family-Individual	Nucleotide change	Amino Acid change	Exon (Zygosity, Segregation)	Poly-phen	SIFT	Mutantaster	Amino acid conservation to species	EVS allele frequencies in EA	Gender	Ethnic origin	Parental Consanguinity	Age of onset	Biopsy	Therapy and response	Extrarenal Manifestations	Reference	Method
<b><i>NPHS2</i></b>																	
A3231-22	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	GG=0/GA=0/AA=4300	F	African-Arabic	Y	5 yrs 2 mo	MPGN	SR	ND	novel	SSe
A1248	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	ND	FSGS (4 yrs 9 mo)	SR, CP-NR, CsA-NR	ND	novel	SSe
A3531-21	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	4 yrs 3 mo	FSGS	SR	ND	novel	SSe
A5099-28	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	5 yrs	FSGS	SR, CP-NR	SS	novel	SSe
A4653-22	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	F	Arabic	N	1 yr 6 mo	MPGN (1 yr 6 mo), FSGS (2 yrs 1 mo)	SR, CP-NR, CsA-NR, MMF-NR	ND	novel	SSe
	c.38-39del2	p.Lys126Argfs*14	1 (het)	NA	NA	NA	NA	-	F	Arabic	N	9 mo	Mesangioloproliferative GN	SR, CP-NR	ND	novel	SSe
A1759-22	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	3 yrs	ND	Steroid-PR	ND	novel	SSe
A4340-21-22	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	1 yr 5 mo	FSGS (2 yrs)	SR	ND	novel	SSe
	c.59C>T	p.Pro20Leu	1 (hom)	0.012	del	DC	H. sapiens	AA=0/AG=14/GG=3694	M	Indian	Y	6 mo	ND	ND	ND	novel	SSe
A4384-21	c.1A>T	p.Met1?	1 (hom)	NA	NA	NA	NA	-	F	Arabic	N	1 yr 5 mo	MesP	SR	ND	novel	SSe
A3649-21	c.42delG	p.Arg15Glufs*84	1 (hom)	NA	NA	NA	NA	-	M	Turkish	Y	3 yrs 2 mo	FSGS	SR	ND	novel	SSe
A2303-21	c.59C>T	p.Pro20Leu	1 (hom)	0.012	del	DC	H. sapiens	AA=0/AG=14/GG=3694	F	Turkish	Y	ND	MPGN (5 yrs 5 mo)	SR	SS	<sup>16</sup>	SSe
A4382-22	c.104_126dupGCC	p.Pro43Alafs*64	1 (het)	NA	NA	NA	NA	-	M	Arabic	Y	1 yr 9 mo	MCNS (2 yrs 1 mo)	SR	ND	novel	SSe
	GCGGGCGCCAG	c.596dupA	p.Asn199Lysfs*14	5 (het)	NA	NA	NA	-								novel	SSe
A5196-21	c.167A>G	p.Glu56Gly	1 (hom)	0.016	del	DC	<i>M. musculus</i>	-	F	African-Arabic	N	1 yr 5 mo	FSGS	SR, CsA-NR, Tac-NR	ND	novel	SSe
A1867	c.259G>T	p.Glu87*	1 (hom)	NA	NA	NA	NA	-	F	Turkish	ND	ND	ND	ND	ND	<sup>28</sup>	SSe
A941-21	c.259G>T	p.Glu87*	1 (het)	NA	NA	NA	NA	-	F	Slavic	N	2 yrs 1 mo	MCNS (2 yrs 2 mo)	SR, CsA-PR	UTA	<sup>28</sup>	SSe
	c.379-2A>C	Splice	2 (het)	NA	NA	NA	NA	-								novel	SSe
1312	c.264_265delGC	p.Pro89Argfs*13	1 (het)	NA	NA	NA	NA	-	F	ND	N	1 yr 7 mo	FSGS (1 yr 8 mo)	SR, CsA-ND	PAS	novel	SSe
	c.378+1G>A	Splice	2 (het)	NA	NA	NA	NA	-								novel	SSe
A2079	c.264_265delGC	p.Pro89Argfs*13	1 (het)	NA	NA	NA	NA	-	F	European	N	1 yr 5 mo	FSGS (1 yr 5 mo)	SR, CsA-R	ND	novel	SSe
	c.378+1GT>TG	Splice	2 (het)	NA	NA	NA	NA	-								novel	SSe
A1840	c.353C>T	p.Pro118Leu	2 (hom)	0.925	del	DC	<i>C. elegans</i>	-	F	Turkish	Y	ND	FSGS (3 yrs)	SR, CsA-NR	ND	<sup>29</sup>	SSe
A2926-21	c.353C>T	p.Pro118Leu	2 (hom)	0.925	del	DC	<i>C. elegans</i>	-	F	Turkish	Y	3 yrs 2 mo	FSGS (3 yrs 6 mo)	SR, CsA-NR	ND	<sup>29</sup>	SSe
A3312-21	c.353C>T	p.Pro118Leu	2 (hom)	0.925	del	DC	<i>C. elegans</i>	-	F	Turkish	Y	2 yrs 2 mo	ND	SR, CP-NR	ND	<sup>29</sup>	SSe
A3318-31	c.353C>T	p.Pro118Leu	2 (hom)	0.925	del	DC	<i>C. elegans</i>	-	M	Turkish	Y	2 mo	ND	ND	ND	<sup>29</sup>	SSe
A167-21	c.353C>T	p.Pro118Leu	2 (hom)	0.925	del	DC	<i>C. elegans</i>	-	F	ND	Y	2 yrs 9 mo	MCNS, FSGS, AN (2 yrs 5 mo)	SR, CsA-PR, ESRD 3 yrs 9 mo	ND	<sup>29</sup>	SSe
A3320-21-22	c.353C>T	p.Pro118Leu	2 (hom)	0.925	del	DC	<i>C. elegans</i>	-	F	Turkish	Y	2 yrs 9 mo	FSGS (2 yrs 10 mo)	SR	ND	<sup>29</sup>	SSe
	c.353C>T	splice	1 (het)	NA	NA	NA	NA	-	M	Asian	Y	1 yr 9 mo	FSGS (1 yr 10 mo)	ND	ND		
A2359-21	c.377delA	p.Lys126Argfs*9	2 (hom)	NA	NA	NA	NA	-	M	Asian	Y	6 mo	ND	SR	ND	novel	SSe
A2161	c.378+1GT>TG	splice	2 (hom)	NA	NA	NA	NA	-	M	Indian	Y	1 yr 5 mo	MCNS (1 yr 5 mo)	SR, CsA-NR	ND	novel	SSe
A1832	c.379-1G>C	splice	2 (hom)	NA	NA	NA	NA	-	M	Turkish	N	11 yr 1 mo	FSGS (11 yr 1 mo)	SR, CP-NR, CsA-NR	ND	novel	SSe
A2269-23	c.385C>T	p.Gln129*	3 (hom)	NA	NA	NA	NA	-	F	Saudi Arabia	Y	2 yrs	ND	SR	ND	<sup>30</sup>	SSe
A3916-22	c.385C>T	p.Gln129* Splice	3 (het) 5 (het)	NA NA	NA NA	NA NA	NA NA	- -	M	Hispanic	N	2 yrs	ND	SR	UTA	<sup>30</sup> novel	SSe SSe

A4284-21	c.388G>A	p.Glu130Lys	3 (hom)	1	del	DC	<i>C. elegans</i>	-	F	Arabic	Y	3 yrs 2 mo	MPGN	ND	ND	novel	Flui	
A4462-22	c.388G>A	p.Glu130Lys	3 (hom)	1	del	DC	<i>C. elegans</i>	-	F	Arabic	Y	ND	MPGN (4 yrs)	SR, CP-NR, MMF	ND	novel	SSe	
A679	c.397delA	p.Arg133Glufs*2	3 (het)	NA	NA	NA	<i>C. elegans</i>	TT=0/TC=8/CC=4292	ND	N								
-21	c.413G>A	p.Arg138Gln	3 (het)	0.999	del	DC	<i>C. elegans</i>	-				ND	ND	ND	ND	novel	Flui	
-22												ND	ND	ND	ND			
A287-21	c.397-398delAG	p.Arg133Serfs*33	3 (het)	NA	NA	NA	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	Russian	N	1 yr	MCNS (1 yr)	SR	N	novel	SSe	
c.413G>A	p.Arg138Gln	3 (het)	0.999	del	DC	<i>C. elegans</i>	-											
A1961	c.397delA	p.Arg133Glufs*2	3 (het)	NA	NA	NA	<i>C. elegans</i>	-	M	White	N	3 yrs 2 mo	FSGS (3 yrs 2 mo)	SR	ND	31	SSe	
c.855_856delAA	p.Arg286Thrfs*17	7 (het)	NA	NA	NA	NA	<i>C. elegans</i>	-							16	SSe		
A354-21	c.412C>T	p.Arg138*	3 (hom)	NA	NA	NA	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	ND	N	ND	MCNS (4 yrs 8 mo)	SR, CsA-CR	AS, CF	16	SSe	
A139-21	c.412C>T	p.Arg138*	3 (hom)	NA	NA	NA	<i>C. elegans</i>	-	M	ND	N	2 yrs 1 mo	FSGS (2 yrs 4 mo)	SR, CP-NR	ND	16	SSe	
A4461-26	c.412C>T	p.Arg138*	3 (hom)	NA	NA	NA	<i>C. elegans</i>	-	F	Arabic	Y	ND	FSGS (2 yrs)	SR, CP-NR	ND	16	SSe	
A3116-21	c.412C>T	p.Arg138*	3 (het)	NA	NA	NA	<i>C. elegans</i>	TT=0/TC=1/CC=4299	Asian	N	11 yr 6 mo	FSGS (12 yrs 5 mo)	CsA	ND	16	SSe		
c.538G>A	p.Val180Met	5 (het)	0.577	del	DC	<i>D. rerio</i>	TT=0/TC=8/CC=4292								16	SSe		
236	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	European	N	2 yrs 5 mo	FSGS (2 yrs 9 mo)	SR	ND	16	SSe	
-21									M			2 mo	FSGS	SR, ESRD 9 yrs 3 mo				
-22																		
348	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	European	N	3 yrs 3 mo	FSGS (5 yrs 11 mo)	SR	SS	16	SSe	
-21									M			2 yrs	FSGS	ND				
-22																		
398	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	European	N	2 yrs 7 mo	FSGS (3 yrs)	SR, CsA-R	ID	16	SSe	
-21									F			8 mo	FSGS (3 yrs)	SR, CsA-R, ESRD 4 yrs	ND			
-23																		
460	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	European	N	ND	MCNS (5 yrs 5 mo)	SR, CP-NR	GR	16	SSe	
-21													MCNS (2 yrs 7 mo)					
-22									F				2 yrs 5 mo	ESRD 3 yrs	SS			
A646	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	European	N	4 yrs 9 mo	ND	SR	ND	16	SSe	
747	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	European	N	3 yrs 5 mo	FSGS (5 yrs 6 mo)	SR, CsA-R	ND	16	SSe	
-21									M			2 yrs 8 mo	FSGS (3 yrs 6 mo)	SR, Plasma exchange, ESRD 3 yrs 10 mo	ND			
-22																		
975	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	ND	N	4 yrs 3 mo	FSGS	SR, CP-NR	ND	16	SSe	
-21									M			1 yr 6 mo	FSGS	ND				
-22																		
1305	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	ND	N	1 yr	FSGS	SR	ND	16	SSe	
A126	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	ND	N	7 mo	FSGS (7 mo)	SR	SS, VUR	16	SSe	
A5193-21	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	Hispanic	N	2 yrs 5 mo	FSGS (4 yrs 5 mo)	SR, CsA-NR	SS	16	SSe	
A825-21	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	Slavic	N	2 mo	FSGS (2 mo)	SR	ND	16	SSe	
A1686	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	European	N	4 yrs 5 mo	FSGS	SR	ND	16	SSe	
A1730	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	German	N	CNS	MCNS (3 mo)	SR	ND	16	SSe	
-21									F			CNS	ND	ESRD 3 yrs	ND			
-22												ND	ND					
A2821-21	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	European	N	ND	ND	ND	SS	16	SSe	
A3025-21	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	White	N	8 yrs 1 mo	FSGS (8 yrs 6 mo)	SR	ND	16	SSe	
A1992	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	European	N	ND	FSGS (7 yrs 8 mo)	ND	ND	16	Flui	
A4002-21	c.413G>A	p.Arg138Gln	3 (hom)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	M	White	N	4 yrs 5 mo	FSGS	SR, CsA-PR	ND	16	SSe	
515	c.413G>A	p.Arg138Gln	3 (het)	0.999	del	DC	<i>C. elegans</i>	TT=0/TC=8/CC=4292	European	N						16	SSe	
-21	c.419delG	p.Gly140Aspfs*41	3 (het)	NA	del	NA	<i>C. elegans</i>	-	M			ND	ND	SR	ID	16	SSe	
-22			3 (het)	NA	NA	NA	<i>C. elegans</i>	NA	M			birth	ND	ND	None			
A266-21	c.413G>A	p.Arg138Gln	3 (het)	0.999	Del	NA	<i>C. elegans</i>	TT=0/TC=8/CC=4292	F	ND	N	1 yr 5 mo	ND	SR, CsA-PR	MC, ID, SS, FD	16	SSe	
c.419delG	p.Gly140Aspfs*41	3 (het)	NA	NA	DC	NA	<i>C. elegans</i>	NA				ND	ND			16	SSe	

355	c.413G>A c.467dupT	p.Arg138Gln p.Leu156Phefs*11	3 (het) 4 (het)	0.999 NA	del NA	DC NA	C. elegans NA	TT=0/TC=8/CC=4292 -	European	N					16 32	SSe SSe	
-21								M		ND	FSGS (4 mo and 3 years 4 mo)	SR, CsA-NR	ND				
-22								F		1 mo	ND	ESRD 6 yrs 7 mo	ND	ND	16 29	Flui Flui	
A2231-21	c.413G>A c.467delT	p.Arg138Gln p.Leu156Cysfs*25	3 (het) 4 (het)	0.999 NA	del NA	DC NA	C. elegans NA	TT=0/TC=8/CC=4292 -	M	White	N	5 yrs 1 mo	ND	ND	16 29		
942	c.413G>A c.503G>A	p.Arg138Gln p.Arg168His	3 (het) 4 (het)	0.999 0.999	del del	DC DC	C. elegans C. elegans	TT=0/TC=8/CC=4292 -	ND	N					16 29	SSe SSe	
-21								M		1 mo	FSGS	ACE-I	hypospadias				
-22								M		1 mo	ND	ACE-I	ND		16 16	SSe SSe	
A52	c.413G>A c.538G>A	p.Arg138Gln p.Val180Met	3 (het) 5 (het)	0.999 0.577	del del	DC DC	C. elegans <i>D. rerio</i>	TT=0/TC=8/CC=4292 TT=0/TC=1/CC=4299	F	ND	N	9 yrs 4 mo	FSGS	SR, CsA-PR	ND	16 16	
-21								F	ND	ND	ND	ND	ND	ND			
-22								F	ND	ND	ND	ND	ND	ND			
A1990	c.413G>A c.643C>T	p.Arg138Gln p.Gln215*	3 (het) 5 (het)	0.999 NA	del NA	DC NA	C. elegans NA	TT=0/TC=8/CC=4292 -	F	White	N	8 mo	MCNS (8 mo)	SR, CsA-NR	ND	16 31	SSe SSe
1261	c.413G>A c.686G>A	p.Arg138Gln p.Arg229Gln	3 (het) 5 (het)	0.999 0.313	del del	DC DC	C. elegans <i>X. tropicalis</i>	TT=0/TC=8/CC=4292 TT=2/TC=319/CC=3979	M	ND	ND	3 yrs 7 mo	FSGS with MesP (3 yrs 10 mo)	SR, CsA-NR	ND	16 33	SSe SSe
A858	c.413G>A c.686G>A	p.Arg138Gln p.Arg229Gln	3 (het) 5 (het)	0.999 0.313	Del del	DC DC	C. elegans <i>X. tropicalis</i>	TT=0/TC=8/CC=4292 TT=2/TC=319/CC=3979	White	N						16 33	SSe SSe
-24								M		ND	ND	ND	ND	ND			
-25								M		ND	ND	ND	ND	ND			
-26								M		ND	ND	ND	ND	ND			
A1112	c.413G>A c.790G>T	p.Arg138Gln p.Glu264*	3 (het) 6 (het)	0.999 NA	del NA	DC NA	C. elegans NA	TT=0/TC=8/CC=4292 -	M	European	N	3 yrs 6 mo	FSGS	SR, CsA-PR	ND	16 34	SSe SSe
A2084	c.413G>A c.856delA	p.Arg138Gln p.Arg286Aspfs*7	3 (het) 7 (het)	0.999 0.999	del NA	DC NA	C. elegans NA	TT=0/TC=8/CC=4292 -	ND	ND					16 novel	SSe SSe	
-21								ND		ND	ND	ND	ND	ND			
-22								ND		1 yr 1 mo	FSGS (1 yr 1 mo)	SR	SR	ND	ND		
A2432-21	c.413G>A	p.Arg138Gln	3 (het)	0.999	del	DC	C. elegans	TT=0/TC=8/CC=4292	F	European	N	ND	ND	GR	16	SSe	
A268-21	c.868G>A	p.Val290Met	7 (het)	0.989	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	F	ND	N	13 yrs 9 mo	MPGN (14 yrs 2 mo), MCNS (17 yrs 3 mo)	SR, CsA	ND	35	SSe
c.413G>A c.868G>A	p.Arg138Gln p.Val290Met	3 (het) 7 (het)	0.999 0.989	del del	DC DC	C. elegans <i>D. rerio</i>	TT=0/TC=8/CC=4292 TT=0/TC=1/CC=4299	F	ND	N	13 yrs 9 mo	MPGN (14 yrs 2 mo), MCNS (17 yrs 3 mo)	SR, CsA	ND	16 35	SSe SSe	
A4426-21	c.413G>A c.868G>A	p.Arg138Gln p.Val290Met	3 (het) 7 (het)	0.999 0.989	del del	DC DC	C. elegans <i>D. rerio</i>	TT=0/TC=8/CC=4292 TT=0/TC=1/CC=4299	M	European	N	ND	MCNS (27 years), FSGS (30 years)	ND	ND	16 35	SSe SSe
A49	c.413G>A c.868G>A	p.Arg138Gln p.Val290Met	3 (het) 7 (het)	0.999 0.989	del del	DC DC	C. elegans <i>D. rerio</i>	TT=0/TC=8/CC=4292 TT=0/TC=1/CC=4299	M	ND	N	14 yrs 3 mo	FSGS (3 yrs 6 mo, 13 yrs mo)	SR, CsA-NR, CP-NR	ND	16 35	SSe SSe
A2547-21	c.413G>A c.1150T>C	p.Arg138Gln p.'384Glnext*7	3 (het) 8 (het)	0.999 NA	del NA	DC NA	C. elegans NA	TT=0/TC=8/CC=4292 -	F	European	N	5 yrs 5 mo	MCNS (5 yrs 5 mo)	SR, CsA	ND	16 novel	SSe SSe
A3679	c.416T>G	p.Leu139Arg	3 (hom)	0.999	del	DC	C. elegans	-	M	Hispanic	N	3 yrs 10 mo	FSGS (3 yrs 10 mo)	SR, MMF-NR, CsA-PR	ND	36	SSe
-22								M		1 yr 9 mo							
-23								M		ND							
A3133-21	c.419delG	p.Gly140Aspfs*41	3 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	5 yrs 8 mo	FSGS (6 yrs)	ND	16	Flui	
A4603-21	c.419delG	p.Gly140Aspfs*41	3 (hom)	NA	NA	NA	NA	-	F	Arabic-african	N	7 months	MPGN	SR, CP-NR	ND	16	Flui
A1645	c.419delG c.506T>C	p.Gly140Aspfs*41 p.Leu169Pro	3 (het) 4 (het)	NA 0.991	NA del	NA DC	NA <i>D. rerio</i>	-	M	Turkish	N	1 yr	DMS (1 yr) and FSGS (7 yrs 4 mo)	SR, CP-NR	ND	16 32	SSe SSe
A2057-21	c.451+3A>T c.868G>A	Splice p.Val290Met	3 (het) 7 (het)	NA 0.989	NA del	NA DC	NA <i>D. rerio</i>	TT=0/TC=1/CC=4299	F	European	N	5 yrs 3 mo	ND	ND	ND	37 35	SSe SSe
1334	c.467dupT	p.Leu156Phefs*11	4 (hom)	NA	NA	NA	NA	-	M	ND	Y	2 yrs 9 mo	FSGS	SR, CsA-NR	ND	32	SSe
A28-21	c.467dupT	p.Leu156Phefs*11	4 (hom)	NA	NA	NA	NA	-	F	Turkish	Y	5 yrs 5 mo	FSGS (5 yrs 5 mo)	SR, CP-NR, CsA-NR	SS	32	SSe
-22								M		1 yr 1 mo							
A3577-21	c.467dupT	p.Leu156Phefs*11	4 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	6 yrs 6 mo	FSGS	SR	ND	32	SSe
A4624-21	c.467dupT	p.Leu156Phefs*11	4 (hom)	NA	NA	NA	NA	-	F	Arabic-african	Y	1 yr 8 mo	MPGN (1 yr 8 mo)	SR, CP-NR, CsA-NR	ND	32	SSe
A818-21	c.467dupT	p.Leu156Phefs*11	4 (hom)	NA	NA	NA	NA	-	M	Turkish	Y	3 yrs	FSGS (3 yrs 9 mo)	SR, CsA, CP-NR	ND	32	SSe
A270-21	c.467dupT c.948delT	p.Leu156Phefs*11 p.Ala317Leufs*31	4 (het) 8 (het)	NA NA	NA NA	NA NA	NA NA	-	F	ND	N	2 yrs 7 mo	MCNS (2 yrs 7 mo), FSGS (3 yrs 4 mo)	SR, CP, CsA-PR	SS	32 38	SSe SSe

A2278-21	c.467dupT c.779T>A	p.Leu156Phefs*11 p.Val260Glu	4 (het) 6 (het)	NA 0.991	NA del	NA DC	NA <i>C.elegans</i>	-	F	Arabic	ND	1 yr	FSGS (3 yrs 7 mo, 4 yrs 3 mo)	SR, CsA-NR, MMF	bilateral VUR	<sup>32</sup> 29	SSe SSe
A4193-23	c.479A>G	p.Asp160Gly	4 (hom)	1	del	DC	<i>D. melanogaster</i>	-	M	Arabic	Y	1 yr 5 mo	ND	ND	ND	<sup>16</sup>	SSe
A1934	c.486C>A	p.Tyr162*	4 (hom)	NA	NA	NA	NA	-	M	Hispanic	N	2 mo	FSGS	SR	LHV	novel	SSe
A5175-21	c.502C>T	p.Arg168Cys	4 (hom)	1	del	DC	<i>C. elegans</i>	-	M	Yemeni	Y	2 yrs	ND	SR	ND	<sup>29</sup>	SSe
A4008-23	c.503G>A	p.Arg168His	4 (hom)	0.999	del	DC	<i>C. elegans</i>	-	M	Arabic	Y	1 yr 5 mo	cFSGS (2 yrs 2 mo)	SR, CP-NR	ND	<sup>29</sup>	SSe
A1897	c.503G>A	p.Arg168His	4 (hom)	0.999	del	DC	<i>C. elegans</i>	-	F	Turkish	Y	2 yrs 7 mo	FSGS (2 yrs 7 mo)	SR	ND	<sup>29</sup>	SSe
A4327-23	c.503G>A	p.Arg168His	4 (hom)	0.999	del	DC	<i>C. elegans</i>	-	F	Arabic	Y	5 yrs 6 mo	FSGS (3 yrs 2 mo)	SR, CP-NR, CsA- NR	Umbilical hernia	<sup>29</sup>	SSe
A2564-21	c.538G>A	p.Val180Met	5 (hom)	0.577	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	ND	ND	ND	ND	ND	ND	ND	<sup>16</sup>	SSe
A3379-21	c.538G>A	p.Val180Met	5 (hom)	0.577	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	F	Arabic	Y	10 yrs 11 mo	FSGS	SR, CP, CsA-NR	ND	<sup>16</sup>	SSe
A3574-21	c.538G>A	p.Val180Met	5 (hom)	0.577	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	M	Arabic	Y	5 yrs 4 mo	IgM nephropathy (5 yrs 4 mo)	SR, CP-PR, CsA- PR, MMF	ND	<sup>16</sup>	SSe
A1071-21	c.538G>A	p.Val180Met	5 (hom)	0.577	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	M	Turkish	Y	11 yr 5 mo	FSGS (11 yr 5 mo)	SR, SP-NR, CsA- NR	ND	<sup>16</sup>	SSe
A3035-21	c.538G>A	p.Val180Met	5 (hom)	0.577	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	F	Arabic	Y	3 yrs 5 mo	FSGS	SR, RTX-NR, MMF- NR	ND	<sup>16</sup>	SSe
A147-21	c.593A>C	p.Glu198Ala	5 (hom)	0.808	del	DC	<i>D. rerio</i>	-	M	Turkish	Y	3 yrs 6 mo	FSGS (8 yrs 5 mo)	SR, CP, CsA-NR	ND	novel	SSe
A4653-31	c.596dupA	p.Asn199Lysfs*14	5 (hom)	NA	NA	NA	NA	No	F	Arabic	Y	1 yr 3 mo	FSGS	SR, CP-NR	ND	novel	SSe
A4341-23	c.596dupA	p.Asn199Lysfs*14	5 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	4 yrs	FSGS (6 yrs 2 mo)	SR, CP-NR	Asthma	novel	SSe
A4383-21	c.596dupA	p.Asn199Lysfs*14	5 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	5 yrs 3 mo	ND	SR, CP-PR	ND	novel	SSe
A3792-21	c.686G>A c.826_833dupCAC TCACT	p.Arg229Gln p.Ala279Thrfs*17	5 (het) 7 (het)	0.313 NA	del	DC	<i>X. tropicalis</i> NA	TT=2/TC=319/CC=3979	F	European	N	8 yrs	FSGS, MPGN (8 yrs)	SR	HA	<sup>33</sup>	SSe novel SSe
A3447	c.686G>A c.841G>A	p.Arg229Gln p.Glu281Lys	5 (het) 7 (het)	0.313 0.991	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	White	Y						<sup>33</sup>	SSe novel SSe
-21 -22									F			3 yrs 22 yrs 5 mo	ND FSGS (22 yrs 6 mo)	ND SR	ND ND		
370	c.686G>A c.851C>T	p.Arg229Gln p.Ala284Val	5 (het) 7 (het)	0.313 0.998	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	European	N						<sup>33</sup> 35	SSe SSe
-33 -31									F M			9 yrs 24 yrs	FSGS (15 yrs 6 mo) FSGS (24 yrs)	SR SR, CsA-NR, CP- NR	ND ND		
489	c.686G>A c.851C>T	p.Arg229Gln p.Ala284Val	5 (het) 7 (het)	0.313 0.998	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	European	N						<sup>33</sup> 35	SSe SSe
-24 -27									M F			11 yr 6 mo 3 yrs 4 mo	MesP (13 yrs 8 mo) FSGS (3 yrs 8 mo)	SR, CP-NR SR, CP-NR, CsA- NR	ND ND		
A2200-21	c.686G>A c.851C>T	p.Arg229Gln p.Ala284Val	5 (het) 7 (het)	0.313 0.998	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	F	Hispanic	N	13 yrs	FSGS	SR	ND	<sup>33</sup> 35	SSe SSe
A4934-21	c.686G>A c.851C>T	p.Arg229Gln p.Ala284Val	5 (het) 7 (het)	0.313 0.998	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	F	White	N	26 yrs	FSGS (27 yrs)	SR, CsA-PR	ND	<sup>33</sup> 35	SSe Se
A5243-21	c.686G>A c.851C>T	p.Arg229Gln p.Ala284Val	5 (het) 7 (het)	0.313 0.998	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	M	African- Arabic	Y	12 yrs 7 mo	ND	SR	ND	<sup>33</sup> 35	SSe SSe
A2242-21	c.686G>A c.862G>A	p.Arg229Gln p.Ala288Thr	5 (het) 7 (het)	0.313 0.999	del	DC	<i>X. tropicalis</i> <i>C. elegans</i>	TT=2/TC=319/CC=3979	F	European	N	13 yrs	MCNS (13 yrs), FSGS (14 yrs)	SR, MMF-NR, Tac- NR, CsA-NR	ND ND	<sup>33</sup> 33	SSe SSe
A1698	c.686G>A c.868G>A	p.Arg229Gln p.Val290Met	5 (het) 7 (het)	0.313 0.989	del	DC	<i>X. tropicalis</i> <i>D. rerio</i>	TT=2/TC=319/CC=3979 TT=0/TC=1/CC=4299	F	Central Slavic	N	2 yrs 3 mo	ND	ND	ND	<sup>33</sup> 35	SSe SSe
A1634	c.686G>A c.871C>T	p.Arg229Gln p.Arg291Trp	5 (het) 7 (het)	0.313 0.978	del	DC	<i>X. tropicalis</i> <i>G. gallus</i>	TT=2/TC=319/CC=3979	F	European	N	1 mo	MCNS (2 yrs 10 mo)	ND	ND ND	<sup>33</sup> 16	SSe SSe
A3356-21	c.686G>A c.868G>A	p.Arg229Gln p.Val290Met	5 (het) 7 (het)	0.313 0.989	del	DC	<i>X. tropicalis</i> <i>D. rerio</i>	TT=2/TC=319/CC=3979 TT=0/TC=1/CC=4299	M	White	N	1 yr 6 mo	MPGN (1 yr 6 mo)	SR, CP, CsA-R	ID	<sup>33</sup>	SSe SSe
A4956-21	c.686G>A c.890C>T	p.Arg229Gln p.Ala297Val	5 (het) 8 (het)	0.313 0.627	del	DC	<i>X. tropicalis</i> <i>H. sapiens</i>	TT=2/TC=319/CC=3979	M	Indian	N	4 yrs 4 mo	FSGS (6 yrs 5 mo)	SR, Tac, RTX, CsA-NR	ND	<sup>33</sup> 33	SSe SSe
585	c.686G>A c.898G>C	p.Arg229Gln p.Ala300Pro	5 (het) 8 (het)	0.313 0.953	del	DC	<i>X. tropicalis</i> <i>G. gallus</i>	TT=2/TC=319/CC=3979	European	N						<sup>33</sup> novel	SSe SSe
-21 -13									F F			16 yrs 3 mo 60 yrs	FSGS (16 yrs 3 mo) FSGS (60 yrs)	SR SR	ND ND		

A667	c.686G>A c.916A>T	p.Arg229Gln p.Arg306Trp	5 (het) 8 (het)	0.313 0.983	del del	DC DC	X. tropicalis <i>C. elegans</i>	TT=2/TC=319/CC=3979 -	European	N						33 novel	SSe SSe	
-21								F M			14 yrs 7 mo ND	FSGS ND	Steroids, CsA ND	ND				
-22								M										
A5280-21	c.686G>A c.928G>A	p.Arg229Gln p.Glu310Lys	5 (het) 8 (het)	0.313 0.936	del del	DC DC	X. tropicalis <i>D. rerio</i>	TT=2/TC=319/CC=3979 -	M	European	N	30 yrs	FSGS (30 yrs)	SR, CsA-NR	ND	33 39	SSe SSe	
454	c.686G>A c.929A>T	p.Arg229Gln p.Glu310Val	5 (het) 8 (het)	0.313 0.96	del del	DC DC	X. tropicalis <i>D. rerio</i>	TT=2/TC=319/CC=3979 -		European	N					33 33	SSe SSe	
-21								M M			ND 2 mo	ND FSGS (9 yrs 6 mo)	ND SR, CsA	ND				
-22								M										
1285	c.686G>A c.929A>C	p.Arg229Gln p.Glu310Ala	5 (het) 8 (het)	0.313 0.837	del del	DC DC	X. tropicalis <i>D. rerio</i>	TT=2/TC=319/CC=3979 -	F	ND	N	4 yrs 2 mo	FSGS	SR, CsA-NR	ND	33 novel	SSe SSe	
A3279-31	c.686G>A c.929A>T	p.Arg229Gln p.Glu310Val	5 (het) 8 (het)	0.313 0.96	Del del	DC DC	X. tropicalis <i>D. rerio</i>	TT=2/TC=319/CC=3979 -	F	German	N	ND	ND	SR	ND	33 33	SSe SSe	
A1495	c.686G>A c.965G>C	p.Arg229Gln p.Arg322Pro	5 (het) 8 (het)	0.313 1	del del	DC DC	X. tropicalis <i>C. elegans</i>	TT=2/TC=319/CC=3979 -	F	Indian	N	1 yr 8 mo	MCNS (1 yr 8 mo)	SR, CP-PR	ND	33 40	SSe SSe	
A907-21	c.686G>A c.961delC	p.Arg229Gln p.Leu321Phefs*27	5 (het) 8 (het)	0.313 NA	Del NA	DC NA	X. tropicalis NA	TT=2/TC=319/CC=3979 -	M	Central slavic	N	13 yrs 4 mo	FSGS (13 yrs 4 mo)	SR, CsA-NR	ND	33 novel	SSe SSe	
A239-21	c.686G>A c.979C>T	p.Arg229Gln p.Leu327Phe	5 (het) 8 (het)	0.313 0.997	del del	DC DC	X. tropicalis <i>C. elegans</i>	TT=2/TC=319/CC=3979 -	F	ND	N	4 yrs 2 mo	MCNS with MesP (16 yrs 2 mo)	SR, CsA-PR	ND	33 33	SSe SSe	
A277-21	c.686G>A c.979C>T	p.Arg229Gln p.Leu327Phe	5 (het) 8 (het)	0.313 0.997	del del	DC DC	X. tropicalis <i>C. elegans</i>	TT=2/TC=319/CC=3979 -	F	ND	N	6 yrs	MCNS (19 yrs 9 mo)	SR, CsA-PR	ND	33 33	SSe SSe	
A4326	c.686G>A c.983A>G	p.Arg229Gln p.Gln328Arg	5 (het) 8 (het)	0.313 0.108	del tol	DC DC	X. tropicalis <i>M. musculus</i>	TT=2/TC=319/CC=3979 -		White	N					33 38	SSe SSe	
-21								F F			9 yrs 6 yrs	ND FSGS	ACE-I ACE-I	ND				
-22								F										
A4678-21	c.686G>A c.983A>G	p.Arg229Gln p.Gln328Arg	5 (het) 8 (het)	0.313 0.108	del tol	DC DC	X. tropicalis <i>M. musculus</i>	TT=2/TC=319/CC=3979 -	F	European	N	ND	FSGS (31 yr)	MMF-NR, CsA-NR	ND	33 38	SSe SSe	
1301	c.686G>A c.983A>G	p.Arg229Gln p.Gln328Arg	5 (het) 8 (het)	0.313 0.108	del tol	DC DC	X. tropicalis <i>M. musculus</i>	TT=2/TC=319/CC=3979 -	F	ND	N	10 yrs	MCNS (24 yrs 1 mo)	Steroids, ACE-I	ND	33 38	SSe SSe	
A3169-22	c.686G>A c.1032delT	p.Arg229Gln p.Phe344Leufs*4	5 (het) 8 (het)	0.313 NA	del NA	DC NA	X. tropicalis NA	TT=2/TC=319/CC=3979 NA	F	White	N	14 yrs 10 mo	FSGS (14 yrs 10)	SR	ND	33 41	SSe SSe	
A900-21	c.686G>A c.1032delT	p.Arg229Gln p.Phe344Leufs*4	5 (het) 8 (het)	0.313 NA	del NA	DC NA	X. tropicalis NA	TT=2/TC=319/CC=3979 -	F	European	N	7 mo	MCNS (1 yr 2 mo)	SR, CP-NR	ND	33 41	SSe SSe	
A3453-21	c.714G>T	p.Arg238Ser	5 (hom)	0.925	del	DC	X. tropicalis	-	M	Arabic	Y	4 yrs	ND	SR, Tac-NR	ND	29	SSe	
A3120-21	c.779T>A	p.Val260Glu	6 (hom)	0.991	del	DC	<i>C. elegans</i>	-	F	Arabic	Y	9 mo	FSGS (1 yr 4 mo)	SR	ND	29	SSe	
A2337-21	c.779T>A	p.Val260Glu	6 (hom)	0.991	del	DC	<i>C. elegans</i>	-	F	Arabic	N	ND	MPGN, secondary FSGS (2 yrs 1 mo)	ND	ND	29	SSe	
A3183-21	c.779T>A	p.Val260Glu	6 (hom)	0.991	del	DC	<i>C. elegans</i>	-	F	Arabic	Y	1 yr	FSGS (1 yr)	SR	ND	29	SSe	
A4329-23	c.779T>A	p.Val260Glu	6 (hom)	0.991	del	DC	<i>C. elegans</i>	-	F	Arabic	N	1 yr 5 mo	MPGN (2 yrs)	SR	ND	29	SSe	
1336	c.868G>A	p.Val290Met	7 (hom)	0.989	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	F	ND	Y	9 mo	MCNS (12 yrs)	SR	ND	35	SSe	
A1616	c.868G>A	p.Val290Met	7 (hom)	0.998	del	DC	<i>D. rerio</i>	TT=0/TC=1/CC=4299	F	White	N	ND	ND	ND	ND	35	Flui	
A4705	c.877A>T	p.Ile293Phe	8 (hom)	0.999	del	DC	<i>C. elegans</i>	-		Hispanic	Y					novel	SSe	
-21								F F			13 yrs 8 yrs	ND FSGS (ND)	SR, CP-NR CP-NR	ND				
-22								F										
A1430	c.883G>A	p.Ala295Thr	8 (hom)	1	del	DC	<i>C. elegans</i>	-	M	Turkish	Y	9 yrs 5 mo	FSGS (9 yrs 5 mo)	ND	ND	novel	SSe	
A2239-21	c.926C>T	p.Ala309Val	8 (hom)	0.742	del	DC	<i>C. elegans</i>	-	M	Turkish	N	ND	FSGS (ND)	ND	ND	novel	Flui	
A3541	c.934C>G	p.Leu312Val	8 (hom)	0.677	del	DC	X. tropicalis	-		Arabic	Y					31	SSe	
-22								F M F			9 yrs 5 mo 8 yrs 5 yrs	MesP (9 yrs 6 mo) MesP (5 yrs 5 mo) ND	ND ND ND	SS SS SS				
-23								M										
-24								F										
A3828-21	c.946C>T	p.Pro316Ser	8 (hom)	0.909	del	DC	<i>C. elegans</i>	-	F	Indian	Y	3 yrs 1 mo	FSGS (4 yrs 4 mo)	SR	ND	novel	SSe	
1058	c.1150T>C	p.*384Glnext*7	8 (hom)	NA	NA	NA	NA	-		Turkish	Y	ND ND	ND ND	ND SR	ND ND	novel	SSe	
-41								M F										
-42								F										
<b>NPHS1</b>																		
A1803-21	c.139delG	p.Ala47Profs*81	2 (hom)	NA	NA	NA	NA	-	M	White	N	birth	MCNS (1 mo)	CsA-NR	ND	novel	Flui	
A1893-21	c.139delG c.3595-2A>G	p.Ala47Profs*81 splice	2 (het) 29 (het)	NA NA	NA	NA	NA	-	F	Hispanic	N	birth	ND	ND	ND	novel	SSe	
A657-21	c.313G>A c.1913A>G	p.Asp105Asn p.Tyr638Cys	3 (het) 14 (het)	1 0.999	del del	DC DC	<i>D. melanogaster</i> <i>D. rerio</i>	-	F	African-American	N	1 mo	FSGS (1 mo)	CsA	ND	42 novel	Flui	

A2559-21	c.313G>A c.2928G>T	p.Asp105Asn p.Arg976Ser	3 (het) 22 (het)	1 0.873	del del	DC DC	D. <i>melanogaster</i> <i>D. melanogaster</i>	AA=0/AC=2/CC=4298	M	African-American	N	3 yrs 8 mo	MCNS (3 yrs 8 mo)	ND	ND	42 43	Flui
A1480-21	c.319G>A c.3244G>A	p.Alanine107Thr p.Gly1082Arg	3 (het) 24 (het)	0.929 0.994	del del	DC PMP	D. <i>melanogaster</i> <i>X. tropicalis</i>	TT=0/TC=0/CC=2203 TT=0/TC=0/CC=2203	M	European	N	5 yrs 8 mo	ND	ND	ND	43 novel	Flui
A1641-21	c.398-1G>A c.3478C>T	splice p.Arg1160*	3 (het) 27 (het)	NA NA	NA NA	NA NA	D. <i>melanogaster</i> <i>D. rerio</i>	-	M	European	N	1 mo	ND	ND	ND	44 novel	SSe
A915-21	c.468C>G c.2928G>T	p.Tyr156* p.Arg976Ser	4 (het) 22 (het)	NA 0.995	NA del	NA DC	D. <i>melanogaster</i> <i>C. elegans</i>	AA=0/AC=2/CC=4298	M	European	N	5 yrs	MCNS (5 yrs)	ND	ND	44 43	Flui
A4960-21	c.500C>T	p.Pro167Leu	4 (hom)	0.988	del	DC	D. <i>melanogaster</i>	-	M	Indian	Y	1 yr	ND	ND	ND	45 novel	SSe
A3850 -21 -22	c.513delGTG c.1316A>G	p.Ile171_Thr172delins p.Tyr439Cys	4 (het) 11 (het)	NA 1	NA del	NA DC	D. <i>melanogaster</i>	-	F F	Egyptian	Y	2 mo 2 mo	MPGN (3 yrs) ND	ND	ND	novel novel	Flui
A3583-22	c.515-517delCCA	p.Thr172del	4 (hom)	NA	NA	NA	M. <i>musculus</i>	-	M	Arabic	Y	2 mo	CNS (2 mo)	ESRD 5 yrs after onset	Subaortic stenosis	46	Flui
A3490-21	c.532C>T c.2928G>T	p.Gln178* p.Arg976Ser	5 (het) 22 (het)	NA 0.995	NA del	NA DC	D. <i>melanogaster</i>	AA=0/AC=2/CC=4298	F	White	N	10 yrs 5 mo	FSGS (10 yrs 5 mo)	CsA	ND	44 43	Flui
A3628-21	c.563A>T c.791C>G	p.Asn188Ile p.Pro264Arg	5 (het) 7 (het)	0.573 0.675	tol tol	PMP PMP	X. <i>tropicalis</i> M. <i>musculus</i>	AA=0/AT=84/TT=4216 CC=1/CG=133/GG=4166	M	Indian	N	1 yr 4 mo	MCNS (3 yrs 3 mo)	ND	ND	47 47	Flui
A669-21	c.614_621delinsTT	p.Thr205_Arg207delinsll e	6 (hom)	NA	NA	NA	NA	-	F	Arabic	N	birth	ND	ND	ND	novel	SSe
A1543-21	c.614_621delinsTT	p.Thr205_Arg207delinsll e	6 (het)	NA	NA	NA	NA	-	M	White	N	1 mo	ND	ND	ND	48	SSe
	c.1307_1308dupAC	p.Val437fs*2	10 (het)	NA	NA	NA	NA									novel	
A1943-21	c.614_621delinsTT	p.Thr205_Arg207delinsll e	6 (het)	NA	NA	NA	NA	-	M	European	N	1 mo	Finnish type (1 mo)	ND	ND	novel	SSe
	c.1715A>G	p.Ser572Gly	13 (het)	1	del	DC	D. <i>melanogaster</i>									novel	
A5242-22	c.617C>A	p.Pro206His	6 (hom)	1	del	DC	X. <i>tropicalis</i>	-	F	Arab	Y	2 yr	ND	ND	HA	novel	Flui
A3652-21	c.766C>T c.1234G>A	p.Arg256Trp p.Gly412Ser	7 (het) 10 (het)	1 0.999	del del	PMP DC	D. <i>melanogaster</i> D. <i>rerio</i>	TT=0/TC=1/CC=4299	M	Indian	Y	5 yrs 2 mo	MCNS (11 yrs 7 mo)	ND	ND	48 novel	Flui
A2070-21	c.791C>G	p.Pro264Arg	7 (hom)	0.675	tol	PMP	D. <i>melanogaster</i>	-	M	Turkey	N	ND	ND	ND	ND	47	Flui
A1619-21	c.791C>G c.1223G>A	p.Pro264Arg p.Arg408Gln	7 (het, p) 10 (het, m)	0.675 1	tol del	PMP DC	D. <i>melanogaster</i> D. <i>rerio</i>	-	M	African American	N	11 yr 7 mo	FSGS (11 yrs 7 mo)	ND	ND	47 46	Flui
A1739-21	c.791C>G c.3151A>G	p.Pro264Arg p.Thr1051Ala	7 (het) 23 (het)	0.675 0.016	tol tol	PMP PMP	D. <i>melanogaster</i> D. <i>rerio</i>	-	M	Arab	Y	10 yr	FSGS (10 yrs)	ND	ND	47 novel	Flui
A5144-23	c.802C>T	p.Arg268*	7 (hom)	NA	NA	NA	NA	-	F	Arab	Y	4 days	ND	ND	ND	49	Flui
A3380-21	c.928G>A c.2816-3T>G	p.Asp310Asn splice	8 (het) 21 (het)	0.99 NA	del NA	DC NA	D. <i>melanogaster</i>	-	M	Asian	ND	1 mo	ND	ND	ND	50 novel	Flui
A4400-22	c.1020delT	p.Ser341Valfs*17	9 (hom)	NA	NA	NA	NA	-	M	Egyptian	N	3 mo	ND	ND	HA	novel	Flui
A4339-26	c.1040G>A	p.Gly347Glu	9 (hom)	1	del	DC	D. <i>melanogaster</i>	-	M	Arab	Y	1 mo	ND	ND	ND	45	Flui
A4378-21	c.1040G>A	p.Gly347Glu	9 (hom)	1	del	DC	D. <i>melanogaster</i>	-	F	Egyptian	N	4 mo	ND	ND	Intestinal obstruction novel	Flui	
A2094 -22 -21	c.1089C>G c.2928G>T	p.Ser363Arg p.Arg976Ser	9 (het) 24 (het)	0.922 0.995	del del	PMP DC	D. <i>melanogaster</i> D. <i>melanogaster</i>	AA=0/AC=2/CC=4298	M M	European	N	3 mo 1 yr	ND FSGS (ND)	CP-NR SR, CP-NR	ND mitralis valve prolapse	novel SSe	Flui SSe
A3543-22	c.1096A>C	p.Ser366Arg	9 (hom)	1	del	DC	D. <i>rerio</i>	-	M	Serbian	N	4 days	ND	ND	ND	46	Flui
A2030-21	c.1096A>C c.3478C>T	p.Ser366Arg p.Arg1160*	9 (het) 27 (het)	0.997 NA	del NA	DC NA	D. <i>melanogaster</i> NA	-	M	Montenegrin	N	1 yr 8 mo	ND	ND	ND	46 46	SSe
A2617-21	c.1099C>T	p.Arg367Cys	9 (Hom)	1	del	DC	M. <i>musculus</i>	-	F	European	Y	1 yr	Finnish type (1 yr)	ND	ND	novel	SSe
A2062-21	c.1099C>T c.2625G>A	p.Arg367Cys p.Trp875*	9 (het) 19 (het)	1 NA	del NA	DC NA	M. <i>musculus</i> NA	-	M	Chinese	N	1 mo	ND	ND	Hypothyroidism 47 44	Flui	
A4444-21	c.1099C>T c.3286+2T>C	p.Arg367Cys splice	9 (het) 24 (het)	1 NA	del NA	DC NA	M. <i>musculus</i> NA	-	M	Indian	N	3 mo	ND	ND	deafness, MC, FD novel 39	Flui	
A5128-22	c.1219C>T	p.Arg407Trp	10 (hom)	0.938	del	PMP	D. <i>rerio</i>	-	F	Indian	Y	1 mo	ND	ND	ND	45	SSe
A5068-21	c.1219C>T c.2422delC	p.Arg407Trp p.Leu808Trpfs*39	10 (het, m) 16 (het, p)	0.938 NA	del NA	PMP NA	D. <i>rerio</i> NA	-	M	Indian	N	1 mo	ND	ND	ND	45	SSe





A4431-21	c.610delA	p.Thr204Glnfs*6	3 (hom, p, m)	NA	NA	NA	NA	-	F F	Turkish	Y	17 yrs 8 yrs	FSGS MPGN (16 yr)	ESRD (22 yrs) ND	ND ND	8	Flui
A1419-21	c.1632T>G	p.Tyr544*	12 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	1 yr 7 mo	ND	ND	ND	novel	
<b><u>SMARCAL1</u></b>																	
A3146-21	c.49C>T c.836T>C	p.Arg17* p.Phe279Ser	4 (het) 5 (het)	NA 0.985	NA tol	NA DC	C. intestinalis	-	F	European	N	9 yrs	FSGS (10 yrs)	-	ID 21 58	Flui	
A3877-21	c.68G>T c.1129G>C	p.Arg23Leu p.Glu377Gln	4 (het) 7 (het)	1 0.425	del tol	DC PMP	C. elegans D. rerio	CC=1/CG=76/GG=4223	M	Indian	N	6 yrs	MCNS (10 yrs), FSGS (ND)	CP-PR	deafness novel 59	Flui	
F979-21	c.836T>C c.1930C>T	p.Phe279Ser p.Arg644Trp	4 (het, m) 12 (het, p)	0.995 1	NA NA	NA NA	C. intestinalis C. elegans	-	F	Arabic-Asian	N	4 yrs	FSGS+MesP (5 yrs 5 mo)	SR, CP-NR, CsA-PR, dialysis at 8 yrs	58 21	Flu	
A968-21	c.1129G>C	p.Glu377Gln	7 (hom)	0.425	tol	PMP	D. rerio	CC=1/CG=76/GG=4223	F	African	N	10 yrs	FSGS (10 yrs)	SR, CP	ND 59	Flui	
A925-21	c.1736C>A	p.Ser579*	12 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	3 yrs	FSGS (4 yrs)	deceased (7 yrs)	SIDD, NHL 21	Flui	
A4162-21	c.1736C>A	p.Ser579*	12 (hom)	NA	NA	NA	NA	-	F	European	N	4 yrs	FSGS (4 yrs)	SR, CsA	VSD, PDA, celiac disease, HU	21	Flui
F310-21	c.1756C>T	p.Arg586Trp	12 (hom)	1	del	DC	C. elegans	-	M	Italian	Y	12 yrs	ND	ESRD (22 yrs), NTX (22 yrs)	SED	SSe	
-22									M			8 yrs	ND	ESRD (12 yrs), deceased (12 yrs)	SED		
-23									M			11 yr	ND	ND	SED		
A1683-21	c.1756C>T	p.Arg586Trp	12 (hom ,m,p)	1	del	DC	C. elegans	-	M	White	Y	7 yrs	FSGS (7yrs)	SR, CP-NR	BLC, macular pigment anomaly 21	Flui	
A3623-21	c.1756C>T	p.Arg586Trp	12 (hom)	1	del	DC	C. elegans	-	F	Indian	N	7 yrs	FSGS (8 yrs)	ND	SS 21	Flui	
A3700-21	c.1756C>T	p.Arg586Trp	12 (hom)	1	del	DC	C. elegans	-	M	Indian	N	10 yrs	FSGS (10 yrs)	ND	ND 21	Flui	
A3090-21	c.1859G>A c.2542G>T	p.Trp620* p.Glu848*	13 (het) 18 (het)	NA NA	NA NA	NA NA	NA	-	M	European	N	4 yrs	FSGS (4 yrs)	ND	Café au Lait maculas, SS 21	Flui	
A3922-22	c.1860G>A	p.Trp620*	13 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	8 yrs	FSGS (8 yrs)	SR, CP-PR	ND	novel	Flui
A4708-21	c.1928T>C c.2542G>T	p.Leu643Pro p.Glu848*	13 (het)	0.999	del	DC	D. melanogaster	-	M	White	N	10 yrs	cFSGS (10 yrs)	RTX	Bilateral hip subluxation novel 21	Flui	
A4380-21	c.2187A>C	p.Leu729Phe	15 (hom)	0.999	del	DC	C. intestinalis	-	M	African-Arabic	ND	5 yrs	ND	SR	URA, SS, FD, SED, HA	novel	Flui
A5017-29	c.2207delT	p.Val736Glyfs*76	15 (hom)	NA	NA	NA	NA	-	M	Yemeni	Y	6 yrs	ND	SR	GR novel	Flui	
A3222-22	c.2459G>T c.2542G>T	p.Arg820Leu p.Glu848*	16 (het)	1 0.085	Del NA	DC NA	C. elegans X. tropicalis	-	F	European	N	1 yrs 11 mo	FSGS 2 yrs 10 mo	ND	SS, FD 21 21	Flui	
<b><u>MYO1E</u></b>																	
A3661-21	c.554A>G c.2464T>A	p.Asp185Gly p.Leu822Met	7 (het) 22 (het)	0.866 0.075	tol tol	DC DC	C. intestinalis D. rerio	CC=0/CT=15/TT=4275	F	Burmese	N	3 yrs	ND	ND	ND	novel novel	Flui
A3163-21	c.1162G>C	p.Asp388His	11 (hom)	1	del	DC	C. intestinalis	-	F	Turkish	N	7 yrs	FSGS (10 yrs)	SR, CP-NR, MMF-NR	ND	novel	Flui
A3191-21	c.1567C>T c.3094_3097delAC AA	p.Arg523Trp p.The103Profs*73	15 (het) 27 (het)	1 NA	del NA	DC NA	C. elegans NA	-	M	Australian	ND	6 mo	ND	ND	ND	novel novel	Flui
F878	c.1807_1808dupGT	p.Lys604*	18 (hom)	NA	NA	NA	NA	-	F	Syrian	Y	1 yr 8 mo	FSGS	SR, CsA-NR	ND	novel	Flui
A3556-21	c.1978C>T	p.Gln660*	19 (hom)	NA	NA	NA	NA	-	M	India	Y	2 mo	MCNS (3 yrs)	SR	ND	novel	Flui
<b><u>LAMB2</u></b>																	
A2356-23	c.736C>T	p.Arg246Trp	7 (hom)	1	del	DC	C.elegans	-	M	Asian	Y	14 mo	Finnish type	ND	blindness, HU 11	Flui	
A2073-21	c.737G>A c.1477delT	p.Arg246Gln p.Cys493Alafs*4	7 (het, p) 11 (het, m)	1 NA	del NA	DC NA	C. elegans NA	-	M	African American	N	2 mo	DMS (2 mo)	ND	ND novel 11	Flui	
A5019-23	c.928T>C c.4198_4199delCT	p.Cys310Arg p.Leu1400Glufs*7	8 (het, p) 26 (het, m)	1 NA	del NA	DC NA	C. elegans NA	-	M	Malaysian	N	5 mo	FSGS (5 mo)	ND	ND novel novel	Flui	
A4683-21	c.1144G>C	p.Ala382Pro	9 (hom)	0.81	tol	DC	M. musculus	-	F	Egyptian	Y	1 yr	No Bx	ID Nystagmus	novel	Flui	

A5143-24	c.1178_1180delTC T	p.Phe393del	9 (hom)	NA	NA	NA	NA	-	F	Arabic	Y	1 mo	FSGS (8 mo)	ESRD (1 yr)	Nystagmus, congenital cataract	novel	Flui
A1613-21	c.1405+1G>A	splice	10 (hom)	NA	NA	NA	NA	-	M	German	N	1 mo	dilated tubules with microcysts	ND	HU	Flui	
A3905-21	c.1405+2insA c.5240del	splice p.Asp1747Alafs*74	10 (het, p) 31 (het, m)	NA	NA	NA	NA	-	F	Indian	N	3 days	DMS (on autopsy)	deceased (2 mo)	ND	novel	Flui
A2373-21	c.1452T>A	p.Cys484*	11 (hom, m, p)	NA	NA	NA	NA	-	M	ND	ND	CNS	ND	ND	Pierson Syndrome	novel	SSe
A5284-21	c.1731+1G>A	splice	13 (hom)	NA	NA	NA	NA	-	F	Asian	Y	1 yr	ND	SR	MC, ID, SS, FD	novel	Flui
A5136-24	c.3100_3101delAG c.4734dupA	p.Ser1034Leufs*20 p.Asp1579Argfs*20	21 (het) 28 (het)	NA NA	NA NA	NA NA	NA NA	-	M	ND	N	2 mo	ND	ND	ND	novel	Flui
A2263-23	c.4537C>T	p.Gln1513*	27 (hom)	NA	NA	NA	NA	-	M	Arabic	Y	3 mo	ND	ND	MC, microcoria, microphthalmia	novel	Flui
A4381-21	c.4582insG	p.Glu1528Glyfs*2	28 (hom)	NA	NA	NA	NA	-	M	Egyptian	Y	2 mo	ND	deceased	FD	novel	Flui
A4981-21	c.5158_5162delAA GGC	p.Lys1720Profs*16	31 (hom)	NA	NA	NA	NA	-	M	Turkish	Y	4 mo	ND	ND	FD, microcoria, glaucoma	novel	Flui
<b>CUBN</b>																	
A807-21	c.348+2T>C	splice	3 (het, m)	NA	NA	NA	NA	GG=0/GA=5/AA=4295	M	European	N	11 yr 11 mo	FSGS (11 yr 11 mo)	SRNS, CsA	Asthma	novel	Flui
A994-21	c.5069C>T c.5518G>A	p.Ala1690Val p.Gly1840Ser	34 (het, p) 37 (hom)	0.994 0.430	tol del	DC PMP	<i>D. rerio</i> <i>D. melanogaster</i>	AA=0/AG=20/GG=4280	-	Hispanic	N	6 yr	FSGS (6 yr)	SRNS	ND	novel novel	Flui Flui
A3316-21	c.4036C>T c.4610C>T	p.Gln1346* p.Ser1537Phe	28 (het, p) 31 (het, m)	NA 0.994	NA del	NA DC	NA <i>D. rerio</i>	-	F	Turkish	N	ND	ND	ND	ND	novel novel	Flui Flui
A4007-21	c.5209+1G>C c.6928_6934delGA GGTAA	Splice p.Glu2310Cysfs*3	35 (het, m) Exon 45 (het, p)	NA NA	NA NA	NA NA	NA NA	-	M	European	N	4 yrs 10 mo	ND	ND	ND	novel <sup>61</sup>	Flui Flui
<b>ITGB4</b>																	
A1697-21	c.469+5G c. 2990C>A	splice p.Pro997His	5 (het) 26 (het)	NA 0.975	NA del	NA DC	NA <i>D. rerio</i>	-	F	African-German	N	9 yrs 9 mo	FSGS (9 yrs 9 mo)	SR, CsA	ND	novel	Flui
<b>PDSS2</b>																	
A3853-22	c.1145C>T	p.Ser382Leu	8 (hom)	1	del	DC	<i>D. rerio</i>	AA:AA=0/AG=0/GG=22 03,	M	African-arabic	Y	1 yr 11 mo	ND	ND	Cerebral palsy, ID	Flui	
A3264-21	c.1151C>A	p.Ala384Asp	8 (hom)	1	del	DC	<i>M. musculus</i>	-	M	Arabic	N	birth	ND	ND	ND	novel	Flui
<b>CFH</b>																	
A3655-21	c.1064A>G	p.Tyr355Cys	8 (hom)	1	del	PMP	<i>X. tropicalis</i>	-	F	Indian	N	9 yrs 4 mo	Diffuse proliferative GN (10 yrs)	Steroids-PR	ND	<sup>62</sup>	Flui
<b>ITGA3</b>																	
A3338-21	c.428G>A	p.Arg143His	4 (hom)	0.882	del	DC	<i>D. melanogaster</i>	-	M	Arabic	Y	4 yrs	ND	ND	ichthyosis, ectodermal dysplasia, Mb. Hirschsprung, TS, kidney dysplasia	novel	Flui
A1605	c.2593delG	p.Asp865Thrfs*38	21 (hom)	N/A	N/A	N/A	N/A	-	M	Turkey	Y	2 mo	ND	ND	Tachydyspno e	novel	Flui

AA=African american. ACE-I=ACE-inhibitors. AN=Alport nephropathy. ASD=atrial septal defect. BLC=bilateral cryptorchidism. cFSGS=collapsing focal segmental glomerulosclerosis. CNS=congenital nephrotic syndrome. CNV=Copy Number Variant. CP=cyclophosphamide. CsA=cyclosporine A. DC=disease causing. DDS=Denys-Drash-syndrome. del=deleterious. DMS=diffuse mesangial sclerosis. EA=European American. ESRD=end-stage renal disease. F=female. FD=facial dysmorphism. Flui=Fluidigm. FSGS=focal segmental glomerulosclerosis. GBM=glomerular basement membrane. GN=glomerulonephritis. GR=growth retardation. HA=heart anomalies. HD=hemodialysis. het=heterozygous. hom=homozygous. HU=hematuria. ID=Intellectual disability. m=maternal. M=male. MC= Microcephalus.

MCNS=minimal change nephrotic syndrome. MesP=mesangial proliferation. MMF=mycophenolate mofetil. mo=month. MPGN=membranoproliferative glomerulonephritis. N=no. NA=not applicable. ND=no data or not done. NHL=non-Hodgkins lymphoma. NR=No response. p=paternal. NTX=kidney transplantation. PAS=pulmonary artery stenosis. PD=peritoneal dialysis. PDA=persistent ductus arteriosus. PMP=polymorphism. PR=partial response. RTX=rituximab. SED=spondylo-epiphyseal dysplasia. SIDD=Schimke immuno-osseous dysplasia. SR=steroid-resistant nephrotic syndrome. SS=short stature. SSe=Sanger sequencing. Tac=tacrolimus. tol=tolerated. TS=tracheal stenosis. URA=unilateral renal agenesis. UTA=urinary tract anomalies. VSD=ventricular septal defect. VUR=vesico-ureteral reflux. WT=Wilms tumor. Y=yes. yrs=years. “-”=no entry.

#Not shown in this table are families with identified disease causing mutations that were published previously by our group: 61 families with *NPHS1* mutations,<sup>41, 45, 48, 63-65</sup> 42 families with *NPHS2* mutations,<sup>38, 41, 63, 65, 66</sup> 50 families with *WT1* mutations,<sup>41, 67-69</sup> 16 families with mutations in *PLCE1*,<sup>18, 65, 70</sup> seven families with *LAMB2* mutations,<sup>41, 65, 71-73</sup> five families with *COQ6* mutations,<sup>6</sup> one family with *TRPC6* mutation,<sup>74</sup> three families with *ITGA3* mutations,<sup>9</sup> one family with *CUBN* mutation,<sup>7</sup> three families with *ADCY4* mutations,<sup>1</sup> one family with *ARHGDI*A mutation.<sup>75</sup>

**Supplemental Table 4. Genotypes and phenotypes of mutations in *WT1* detected by Sanger sequencing and high-throughput sequencing in 35 out of 1,783 families with SRNS.<sup>#</sup>**

Family-Individual	Nucleotide change	Amino acid change	Legacy change	Exon (Zygosity, Segregation)	SIFT	Amino acid conservation to species	EVS allele frequencies in EA	Gender	Ethnic origin	Parental consanguinity	Age of onset	Biopsy (at age)	Therapy and response	Extrarenal Manifestations	Reference	Method
<b>WT1</b>																
A5218-21	c.872+1G>A	splice	IVS4+1G>A	4 (het)	NA	NA	-	M	Arabic	Y	6 mo	bilateral WT	ACE-I, chemotherapy, tumorectomy	ND	novel	SSe
A3167-22	c.1001+6T>G	splice	IVS5+1T>G	5 (het)	NA	NA	-	M	Egyptian	Y	3 yrs	ND	SR	ND	novel	SSe
A1987-21	c.1178G>A	p.Cys376Tyr	p.Cys308Tyr	7 (het)	NA	<i>S. cerevisiae</i>	-	F	White	N	29 yrs	ND	ND	ND	novel	Flui
A4602-21	c.1283G>A	p.Cys428Tyr	p.Cys360Tyr	8 (het)	del	<i>S. cerevisiae</i>	-	F	White	N	2 mo	ND	ND	ND	76	SSe
A3808-21	c.1300C>T	p.Arg434Cys	p.Arg366Cys	8 (het)	del	<i>S. cerevisiae</i>	-	M	White	N	1 mo	DMS (1 mo)	SR	UTM	27	SSe
A2624-21	c.1301G>A	p.Arg434His	p.Arg366His	8 (het)	del	<i>S. cerevisiae</i>	-	M	Asian	N	prenatal	ND	deceased in utero at 31 weeks of gestation	Ambiguous genitalia	77	SSe
A3194-21	c.1301G>A	p.Arg434His	p.Arg366His	8 (het)	del	<i>S. cerevisiae</i>	-	F	Turkish	N	2 mo	ND	ND	MC	77	SSe
A3940-21	c.1301G>A	p.Arg434His	p.Arg366His	8 (het)	del	<i>S. cerevisiae</i>	-	F	Pakistani	N	1 mo	ND	ND	ID	77	SSe
A3947-21	c.1301G>A	p.Arg434His	p.Arg366His	8 (het)	del	<i>S. cerevisiae</i>	-	M	Turkish	N	7 days	ND	Albumin	UTM	77	SSe
A4335-21	c.1301G>A	p.Arg434His	p.Arg366His	8 (het)	del	<i>S. cerevisiae</i>	-	F	White	N	<30 days	DMS (1 mo), MCNS (2 yrs)	ND	UTM	77	SSe
A5212-21	c.1337C>G	p.Thr446Arg	p.Thr378Arg	8 (het)	del	<i>S. cerevisiae</i>	-	F	European	N	5 yrs	FSGS (5 yrs)	SR, CsA	ND	69	SSe
A2370-21	c.1339+5G>A	splice	IVS8+5G>A	8 (het)	NA	NA	-	M	Arabic	Y	5 mo	ND	ND	ND	78	Flui
A2364-21	c.1357T>C	p.Cys453Arg	p.Cys385Arg	9 (het)	del	<i>S. cerevisiae</i>	-	M	European	N	1 yr	DMS (1 yr)	ND	BLC	79	SSe
A4160-21	c.1366T>C	p.Cys456Arg	p.Cys388Arg	9 (het)	del	<i>S. cerevisiae</i>	-	M	European	N	3 mo	ND	ND	UTM, UTM	38	SSe
A3545-21	c.1369C>T	p.Glu457*	p.Glu389*	9 (het)	NA	NA	-	F	White	N	7 mo	DMS (1 yr)	ND	ND	80	SSe
A3015-21	c.1373G>A	p.Arg458Gln	p.Arg390Gln	9 (het)	del	<i>D. rerio</i>	-	F	Hispanic	ND	10 yrs	FSGS (ND)	ND	ND	novel	SSe
A943-21	c.1384C>T	p.Arg462Trp	p.Arg394Trp	9 (het)	del	<i>S. cerevisiae</i>	-	M	German	N	2 yrs	Sclerotic GN	ND	DDS, right WT, BLC	77	SSe
A3526-21	c.1384C>T	p.Arg462Trp	p.Arg394Trp	9 (het)	del	<i>S. cerevisiae</i>	-	M	Hispanic	N	7 yrs	WT right	Chemotherapy	ND	77	SSe
A3715-21	c.1384C>T	p.Arg462Trp	p.Arg394Trp	9 (het)	del	<i>S. cerevisiae</i>	-	M	Arabic	Y	6 mo	ND	ND	FD, UTM	77	SSe
A5022-26	c.1384C>T	p.Arg462Trp	p.Arg394Trp	9 (het)	del	<i>S. cerevisiae</i>	-	M	Arabic	N	3 yrs	DMS (3 yrs)	ND	UTM	77	SSe
A2270-21	c.1384C>T	p.Arg462Trp	p.Arg394Trp	9 (het)	del	<i>S. cerevisiae</i>	-	F	White/Spanish	N	birth	DMS	ND	ND	77	Flui
A2072-21	c.1385G>A	p.Arg462Gln	p.Arg394Gln	9 (het)	del	<i>S. cerevisiae</i>	-	M	African American	N	1 week	ND	ND	Hypospadias, BLC	69	SSe
A4925-21	c.1390G>A	p.Asp464Asn	p.Asp396Asn	9 (het)	del	<i>S. cerevisiae</i>	-	F	White	N	1 mo	DMS (1 mo)	ND	ND	77	SSe
A1726-21	c.1393C>T	p.His465Tyr	p.His397Tyr	9 (het)	del	<i>C. elegans</i>	-	M	Hungarian	N	9 mo	MCNS (1 yr)	ND	BLC	novel	Flui
A3161-21	c.1432+4C>T	splice	IVS9+4C>T	9 (het)	NA	NA	-	F	Turkish	N	9 yrs	FSGS (9 yrs)	SR, CsA-NR	ND	81, 82	SSe
A3671-21	c.1432+4C>T	splice	IVS9+4C>T	9 (het)	NA	NA	-	F	Indian	N	5 yrs	FSGS (7 yrs)	SR	ND	81, 82	SSe
A3911-21	c.1432+4C>T	splice	IVS9+4C>T	9 (het)	NA	NA	-	F	White	N	3 yrs	Thin GBM	SR	UTM	81, 82	SSe
A1684-21	c.1432+4C>T	splice	IVS9+4C>T	9 (het)	NA	NA	-	F	Hispanic	N	2 yrs 5 mo	FSGS (3 yrs)	SR, CP-NR, Tac	ND	81, 82	Flui
A2963-21	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	M	Hispanic	ND	34 yrs	FSGS	ND	ND	79	SSe
A1271-21	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	M	ND	N	7 mo	DMS	ACE-I	FD, UTM, HA	79	SSe
A3707-21	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	F	Hispanic	N	5 yrs	FSGS (9 yrs)	SR	UTM, delayed bone age	79	SSe
A3770-21	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	F	Arabic	N	1 yr	DMS (3 yrs)	Steroids	ND	79	SSe
A3668-22	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	F	Arabic	N	3 yrs	FSGS+MPGN (3 yrs)	SR, CP-NR	ND	79	SSe
A5139-21	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	F	Russian	N	ND	ND	SR, CsA	UTM, VUR	79	SSe
A5141-21	c.1432+5G>A	splice	IVS+5G>A	9 (het)	NA	NA	-	F	White	N	4 yrs	FSGS (4 yrs)	SR, CP, CsA, Tac	ND	79	SSe

AA=African american. ACE-I=ACE-inhibitors. AN=Alport nephropathy. ASD=atrial septal defect. BLC=bilateral cryptorchidism. cFSGS=collapsing focal segmental glomerulosclerosis. CNS=congenital nephrotic syndrome. CNV=Copy Number Variant. CP=cyclophosphamide. CsA=cyclosporine A. DC=disease causing. DDS=Denys-Drash-syndrome. del=deleterious. DMS=diffuse mesangial sclerosis. EA=European American. ESRD=end-stage renal disease. F=female. FD=facial dysmorphism. Flui=Fluidigm. FSGS=focal segmental glomerulosclerosis. GBM=glomerular basement membrane. GN=glomerulonephritis. GR=growth retardation. HA=heart anomalies. HD=hemodialysis. het=heterozygous. hom=homozygous. HU=hematuria. ID=Intellectual disability. m=maternal. M=male. MC=Microcephalus. MCNS=minimal change nephrotic syndrome. MesP=mesangial proliferation. MMF=mycophenolate mofetil. mo=month. MPGN=membranoproliferative glomerulonephritis. N=no. NA=not applicable. ND=no data or not done. NHL=non-Hodgkins lymphoma. NR=No response.

p=paternal. NTX=kidney transplantation. PAS=pulmonary artery stenosis. PD=peritoneal dialysis. PDA=persistent ductus arteriosus. PMP=polymorphism. PR=partial response. RTX=rituximab. SED=spondylo-epiphyseal dysplasia. SIDD=Schimke immuno-osseous dysplasia. SR=steroid-resistant nephrotic syndrome. SS=short stature. SSe=Sanger sequencing. Tac=tacrolimus. tol=tolerated. TS=tracheal stenosis. URA=unilateral renal agenesis. UTA=urinary tract anomalies. VSD=ventricular septal defect. VUR=vesico-ureteral reflux. WT=Wilms tumor. Y=yes. yrs=years. “-”=no entry.

#Not shown in this table are families with identified disease causing mutations that were published previously by our group: 61 families with *NPHS1* mutations,<sup>41, 45, 48, 63-65</sup> 42 families with *NPHS2* mutations,<sup>38, 41, 63, 65, 66</sup> 50 families with *WT1* mutations,<sup>41, 67-69</sup> 16 families with mutations in *PLCE1*,<sup>18, 65, 70</sup> seven families with *LAMB2* mutations,<sup>41, 65, 71-73</sup> five families with *COQ6* mutations,<sup>6</sup> one family with *TRPC6* mutation,<sup>74</sup> three families with *ITGA3* mutations,<sup>9</sup> one family with *CUBN* mutation,<sup>7</sup> three families with *ADCK4* mutations,<sup>1</sup> one family with *ARHGDI*A mutation.<sup>75</sup>

**Supplemental Table 5. Genotypes and phenotypes of mutations in *TRPC6*, *ARHGAP24*, and *INF2* and *LMX1B* detected by Sanger sequencing and high-throughput sequencing in 22 out of 1,783 families with SRNS.<sup>#</sup>**

Family-Individual	Nucleotide change	Amino Acid change	Exon (Zygosity, Segregation)	Poly-phen	SIFT	Mutation -taster	Amino acid conservation to species	EVS allele frequencies in EA	Gender	Ethnic origin	Parental Consanguinity	Age of onset	Biopsy	Therapy and response	Extrarenal Manifestations	Reference	Method
<b><i>TRPC6</i></b>																	
F505-41	c.395T>C	p.Met132Thr	2 (het)	0.801	del	DC	<i>D. rerio</i>	-	M	European	N	8 yrs 6 mo	MCNS (8 yrs) with FSGS	ND	Hypospadias	<sup>74</sup>	SSe
A1657	c.428A>G	p.Asn143Ser	2 (het)	0.998	del	DC	<i>D. rerio</i>	EA:CC=0/CT=0/TT=4299 AA:CC=0/CT=3/TT=8598	F	African American	N	8 yrs	FSGS (8 yrs)	ND	ND	<sup>83</sup>	Flui
A5246-21 A3310-21	c.1195C>T c.2536-2539delAA TA	p.Arg399* p.Asn846Valfs*	4 (het) 11 (het) 12	NA NA NA	NA NA NA	NA NA NA	<i>M. musculus</i>	-	M M	European Turkish	N N	35 yrs 2 yrs 7 mo	FSGS (35 yrs) FSGS (2 yrs 9 mo)	ND ND	ND ND	novel novel	Flui Flui
F1174-21	c.2605C>T	p.Gln869*	12 (het)	NA	NA	NA	<i>M. musculus</i>	-	M	European	N	13 yrs 1 mo	ND	SR transplant at 15 yrs	Factor V leiden	novel	Flui
A2401-31 A664-21 A4717-21	c.2656G>T c.2683C>T c.2684G>T	p.Glu886* p.Arg895Cys p.Arg895Leu	13 (het) 13 (het) 13 (het)	NA 0.905 0.905	NA del del	NA DC DC	<i>D. rerio</i> <i>D. rerio</i>	-	F F M	European Jewish Indian	N N M	ND 3 yrs 2 mo 1 yr 6 mo	ND ND cFSGS (1 yr 8 mo)	ND ND ND	ND ND ND	novel <sup>83</sup> <sup>84</sup>	Flui Flui Flui
<b><i>ARHGAP24</i></b>																	
A4000-21 -22	c.120G>A	p.Trp40*	2 (het)	NA	NA	NA	NA	-	F F	White	N	32 yrs	FSGS	HU	ND	novel	Flui
<b><i>INF2</i></b>																	
A1949-21	c.317G>C	p.Arg106Pro	2 (het)	1	del	DC	<i>D. rerio</i>	-	M	African American	N	6 yrs	FSGS (6 yrs)	SR	ND	<sup>85</sup>	Flui
A1927-11 -21	c.451T>C	p.Cys151Arg	3 (het)	0.987	del	DC	<i>X. tropicalis</i>	-	M M	American American	N	ND 11 yr	ND	ND	Charcot-Marie Tooth	<sup>86</sup>	Flui
A4722-21 A3029-21 A5091-23 -24	c.530G>A c.550G>A c.550G>A	p.Arg177His p.Glu184Lys p.Glu184Lys	4 (het) 4 (het, p) 4 (het)	0.999 0.999 0.999	del	DC DC DC	<i>D. rerio</i> <i>D. rerio</i> <i>D. rerio</i>	-	M M M	European European Indian	N N N	27 yrs ND	FSGS (11 yr) FSGS (27 yrs) FSGS (15 yrs)	SR SR SR, CP	ND ND ND	<sup>85</sup> <sup>24</sup> <sup>24</sup>	Flui Flui Flui
A828-32 -33 -41	c.641G>A	p.Arg214His	4 (het)	0.999	del	DC	<i>D. rerio</i>	-	M M M	Serbian	N	18 yrs ND ND	FSGS (29 yrs) ND ND	SR, ACE-I ND ND	ND	<sup>24</sup>	Flui
A3184-21	c.652C>T	p.Arg218Trp	4 (het, m)	1	del	DC	<i>D. rerio</i>	-	M	European	N	12 yrs	FSGS (13 yrs)	SR, CP, CsA	ND	<sup>24</sup>	Flui
A4017-21 A5050-21	c.653G>A G.658G>A	p.Arg218Gln p.Glu220Lys	4 (het, m) 4 (het, p)	1 0.999	del	DC DC	<i>D. rerio</i> <i>D. rerio</i>	-	M M	European Bulgarian	Y N	22 yrs 17 yrs	FSGS (22 yrs) FSGS (17 yrs)	SR SR, CsA	HTN ND	<sup>24</sup> <sup>24</sup>	Flui Flui
<b><i>LMX1B</i></b>																	
A54-21 A200-21	c.737G>A c.737G>A	p.Arg246Gln p.Arg246Gln	4 (het) 4 (het)	1 1	del	DC DC	<i>C. elegans</i> <i>C. elegans</i>	-	F F	German Turkish	N Y	6 yrs 8 yrs	ND FSGS (8 yrs)	SR SR, ESRD and HD (9 yrs)	familial NS familial NS	<sup>87</sup>	Flui
A2175-21	c.737G>A	p.Arg246Gln	4 (het)	1	del	DC	<i>C. elegans</i>	-	M	Swiss	N	4 yrs	FSGS (4 yrs)	SR, CsA-PR, ACE-I	Factor-XII deficiency	<sup>87</sup>	Flui
A3180-21 -22 -31 -32	c.737G>A	p.Arg246Gln	4 (het)	1	del	DC	<i>C. elegans</i>	-	F	German	N	18 yrs	FSGS (43 yrs)	HD (43 yrs), NTX (47 yrs)	ND	<sup>87</sup>	Flui
									M			32 yrs	FSGS (33 yrs)	HD (44 yrs)	ND		
									F F			ND ND	FSGS (ND) ND	ACE-I ACE-I	ND ND		

AA=African american. ACE-I=ACE-inhibitors. AN=Alport nephropathy. ASD=atrial septal defect. BLC=bilateral cryptorchidism. cFSGS=collapsing focal segmental glomerulosclerosis. CNS=congenital nephrotic syndrome. CNV=Copy Number Variant. CP=cyclophosphamide. CsA=cyclosporine A. DC=disease causing. DDS=Denys-Drash-syndrome. del=deleterious. DMS=diffuse mesangial sclerosis. EA=European American. ESRD=end-stage renal disease. F=female. FD=facial

dysmorphism. Flui=Fluidigm. FSGS=focal segmental glomerulosclerosis. GBM=glomerular basement membrane. GN=glomerulonephritis. GR=growth retardation. HA=heart anomalies. HD=hemodialysis. het=heterozygous. hom=homozygous. HU=hematuria. ID=Intellectual disability. m=maternal. M=male. MC= Microcephalus. MCNS=minimal change nephrotic syndrome. MesP=mesangial proliferation. MMF=mycophenolate mofetil. mo=month. MPGN=membranoproliferative glomerulonephritis. N=no. NA=not applicable. ND=no data or not done. NHL=non-Hodgkins lymphoma. NR=No response. p=paternal. NTX=kidney transplantation. PAS=pulmonary artery stenosis. PD=peritoneal dialysis. PDA=persistent ductus arteriosus. PMP=polymorphism. PR=partial response. RTX=rituximab. SED=spondylo-epiphyseal dysplasia. SIDD=Schimke immuno-osseous dysplasia. SR=steroid-resistant nephrotic syndrome. SS=short stature. SSe=Sanger sequencing. Tac=tacrolimus. tol=tolerated. TS=tracheal stenosis. URA=unilateral renal agenesis. UTA=urinary tract anomalies. VSD=ventricular septal defect. VUR=vesico-ureteral reflux. WT=Wilms tumor. Y=yes. yrs=years. “-“=no entry.

#Not shown in this table are families with identified disease causing mutations that were published previously by our group: 61 families with *NPHS1* mutations,<sup>41, 45, 48, 63-65</sup> 42 families with *NPHS2* mutations,<sup>38, 41, 63, 65, 66</sup> 50 families with *WT1* mutations,<sup>41, 67-69</sup> 16 families with mutations in *PLCE1*,<sup>18, 65, 70</sup> seven families with *LAMB2* mutations,<sup>41, 65, 71-73</sup> five families with *COQ6* mutations,<sup>6</sup> one family with *TRPC6* mutation,<sup>74</sup> three families with *ITGA3* mutations,<sup>9</sup> one family with *CUBN* mutation,<sup>7</sup> three families with *ADCK4* mutations,<sup>1</sup> one family with *ARHGDIA* mutation.<sup>75</sup>

## SUPPLEMENTAL REFERENCES

1. Ashraf, S, Gee, HY, Woerner, S, Xie, LX, Vega-Warner, V, Lovric, S, Fang, H, Song, X, Catran, DC, Avila-Casado, C, Paterson, AD, Nitschke, P, Bole-Feysot, C, Cochat, P, Esteve-Rudd, J, Haberberger, B, Allen, SJ, Zhou, W, Airik, R, Otto, EA, Barua, M, Al-Hamed, MH, Kari, JA, Evans, J, Bierzynska, A, Saleem, MA, Bockenhauer, D, Kleta, R, El Desoky, S, Hacihamdioglu, DO, Gok, F, Washburn, J, Wiggins, RC, Choi, M, Lifton, RP, Levy, S, Han, Z, Salviati, L, Prokisch, H, Williams, DS, Pollak, M, Clarke, CF, Pei, Y, Antignac, C, Hildebrandt, F: ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. *The Journal of clinical investigation*, 123: 5179-5189, 2013.
2. Gupta, IR, Baldwin, C, Auguste, D, Ha, KC, El Andalousi, J, Fahiminiya, S, Bitzan, M, Bernard, C, Akbari, MR, Narod, SA, Rosenblatt, DS, Majewski, J, Takano, T: ARHGDIa: a novel gene implicated in nephrotic syndrome. *J Med Genet*, 50: 330-338, 2013.
3. Lowik, MM, Groenen, PJ, Pronk, I, Lilien, MR, Goldschmeding, R, Dijkman, HB, Levtchenko, EN, Monnens, LA, van den Heuvel, LP: Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. *Kidney international*, 72: 1198-1203, 2007.
4. Sethi, S, Fervenza, FC, Zhang, Y, Smith, RJ: Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 60: 316-321, 2012.
5. Diomedi-Camassei, F, Di Giandomenico, S, Santorelli, FM, Caridi, G, Piemonte, F, Montini, G, Ghiggeri, GM, Murer, L, Barisoni, L, Pastore, A, Muda, AO, Valente, ML, Bertini, E, Emma, F: COQ2 nephropathy: a newly described inherited mitochondrialopathy with primary renal involvement. *Journal of the American Society of Nephrology : JASN*, 18: 2773-2780, 2007.
6. Heeringa, SF, Chernin, G, Chaki, M, Zhou, W, Sloan, AJ, Ji, Z, Xie, LX, Salviati, L, Hurd, TW, Vega-Warner, V, Killen, PD, Raphael, Y, Ashraf, S, Ovunc, B, Schoeb, DS, McLaughlin, HM, Airik, R, Vlangos, CN, Gbadegesin, R, Hinkes, B, Saisawat, P, Trevisson, E, Doimo, M, Casarin, A, Pertegato, V, Giorgi, G, Prokisch, H, Rotig, A, Nurnberg, G, Becker, C, Wang, S, Ozaltin, F, Topaloglu, R, Bakkaloglu, A, Bakkaloglu, SA, Muller, D, Beissert, A, Mir, S, Berdeli, A, Varpizen, S, Zenker, M, Matejas, V, Santos-Ocana, C, Navas, P, Kusakabe, T, Kispert, A, Akman, S, Soliman, NA, Krick, S, Mundel, P, Reiser, J, Nurnberg, P, Clarke, CF, Wiggins, RC, Faul, C, Hildebrandt, F: COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *The Journal of clinical investigation*, 121: 2013-2024, 2011.
7. Ovunc, B, Otto, EA, Vega-Warner, V, Saisawat, P, Ashraf, S, Ramaswami, G, Fathy, HM, Schoeb, D, Chernin, G, Lyons, RH, Yilmaz, E, Hildebrandt, F: Exome sequencing reveals cubilin mutation as a single-gene cause of proteinuria. *Journal of the American Society of Nephrology : JASN*, 22: 1815-1820, 2011.
8. Ozaltin, F, Li, B, Rauhauser, A, An, SW, Soylemezoglu, O, Gonul, II, Taskiran, EZ, Ibsirlioglu, T, Korkmaz, E, Bilginer, Y, Duzova, A, Ozen, S, Topaloglu, R, Besbas, N, Ashraf, S, Du, Y, Liang, C, Chen, P, Lu, D, Vadnagara, K, Arbuckle, S, Lewis, D, Wakeland, B, Quigg, RJ, Ransom, RF, Wakeland, EK, Topham, MK, Bazan, NG, Mohan, C, Hildebrandt, F, Bakkaloglu, A, Huang, CL, Attanasio, M: DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. *Journal of the American Society of Nephrology : JASN*, 24: 377-384, 2013.
9. Has, C, Sparta, G, Kirtsis, D, Weibel, L, Moeller, A, Vega-Warner, V, Waters, A, He, Y, Anikster, Y, Esser, P, Straub, BK, Hausser, I, Bockenhauer, D, Dekel, B, Hildebrandt, F, Bruckner-Tuderman, L, Laube, GF: Integrin alpha3 mutations with kidney, lung, and skin disease. *The New England journal of medicine*, 366: 1508-1514, 2012.
10. Kambham, N, Tanji, N, Seigle, RL, Markowitz, GS, Pulkkinen, L, Uitto, J, D'Agati, VD: Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. *American journal of kidney diseases : the official journal of the National Kidney Foundation*, 36: 190-196, 2000.

11. Zenker, M, Aigner, T, Wendler, O, Tralau, T, Muntefering, H, Fenski, R, Pitz, S, Schumacher, V, Royer-Pokora, B, Wuhl, E, Cochat, P, Bouvier, R, Kraus, C, Mark, K, Madlon, H, Dotsch, J, Rascher, W, Maruniak-Chudek, I, Lennert, T, Neumann, LM, Reis, A: Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. *Human molecular genetics*, 13: 2625-2632, 2004.
12. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. *Cell*, 90: 797-807, 1997.
13. Mele, C, Iatropoulos, P, Donadelli, R, Calabria, A, Maranta, R, Cassis, P, Buelli, S, Tomasoni, S, Piras, R, Krendel, M, Bettoni, S, Morigi, M, Delle Donne, M, Pecoraro, C, Abbate, I, Capobianchi, MR, Hildebrandt, F, Otto, E, Schaefer, F, Macciardi, F, Ozaltin, F, Emre, S, Ibsirlioglu, T, Benigni, A, Remuzzi, G, Noris, M: MYO1E mutations and childhood familial focal segmental glomerulosclerosis. *The New England journal of medicine*, 365: 295-306, 2011.
14. Sanna-Cherchi, S, Burgess, KE, Nees, SN, Caridi, G, Weng, PL, Dagnino, M, Bodria, M, Carrea, A, Allegretta, MA, Kim, HR, Perry, BJ, Gigante, M, Clark, LN, Kisselev, S, Cusi, D, Gesualdo, L, Allegri, L, Scolari, F, D'Agati, V, Shapiro, LS, Pecoraro, C, Palomero, T, Ghiggeri, GM, Gharavi, AG: Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome. *Kidney international*, 80: 389-396, 2011.
15. Kestila, M, Lenkkeri, U, Mannikko, M, Lamerdin, J, McCready, P, Putala, H, Ruotsalainen, V, Morita, T, Nissinen, M, Herva, R, Kashtan, CE, Peltonen, L, Holmberg, C, Olsen, A, Tryggvason, K: Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. *Molecular cell*, 1: 575-582, 1998.
16. Boute, N, Gribouval, O, Roselli, S, Benessy, F, Lee, H, Fuchshuber, A, Dahan, K, Gubler, MC, Niaudet, P, Antignac, C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. *Nat Genet*, 24: 349-354, 2000.
17. Lopez, LC, Schuelke, M, Quinzii, CM, Kanki, T, Rodenburg, RJ, Naini, A, Dimauro, S, Hirano, M: Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. *American journal of human genetics*, 79: 1125-1129, 2006.
18. Hinkes, B, Wiggins, RC, Gbadegesin, R, Vlangos, CN, Seelow, D, Nurnberg, G, Garg, P, Verma, R, Chaib, H, Hoskins, BE, Ashraf, S, Becker, C, Hennies, HC, Goyal, M, Wharram, BL, Schachter, AD, Mudumana, S, Drummond, I, Kerjaschki, D, Waldherr, R, Dietrich, A, Ozaltin, F, Bakkaloglu, A, Cleper, R, Basel-Vanagaite, L, Pohl, M, Griebel, M, Tsygyn, AN, Soylu, A, Muller, D, Sorli, CS, Bunney, TD, Katan, M, Liu, J, Attanasio, M, O'Toole, J, F, Hasselbacher, K, Mucha, B, Otto, EA, Airik, R, Kispert, A, Kelley, GG, Smrcka, AV, Gudermann, T, Holzman, LB, Nurnberg, P, Hildebrandt, F: Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. *Nat Genet*, 38: 1397-1405, 2006.
19. Ozaltin, F, Ibsirlioglu, T, Taskiran, EZ, Baydar, DE, Kaymaz, F, Buyukcelik, M, Kilic, BD, Balat, A, Iatropoulos, P, Asan, E, Akarsu, NA, Schaefer, F, Yilmaz, E, Bakkaloglu, A: Disruption of PTPRO causes childhood-onset nephrotic syndrome. *American journal of human genetics*, 89: 139-147, 2011.
20. Berkovic, SF, Dibbens, LM, Oshlack, A, Silver, JD, Katerelos, M, Vears, DF, Lullmann-Rauch, R, Blanz, J, Zhang, KW, Stankovich, J, Kalnins, RM, Dowling, JP, Andermann, E, Andermann, F, Faldini, E, D'Hooge, R, Vadlamudi, L, Macdonell, RA, Hodgson, BL, Bayly, MA, Savage, J, Mulley, JC, Smyth, GK, Power, DA, Saftig, P, Bahlo, M: Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. *American journal of human genetics*, 82: 673-684, 2008.
21. Boerkoel, CF, Takashima, H, John, J, Yan, J, Stankiewicz, P, Rosenbarker, L, Andre, JL, Bogdanovic, R, Burguet, A, Cockfield, S, Cordeiro, I, Frund, S, Illies, F, Joseph, M, Kaitila, I, Lama, G, Loirat, C, McLeod, DR, Milford, DV, Petty, EM, Rodrigo, F, Saraiva, JM, Schmidt, B, Smith, GC, Spranger, J, Stein, A, Thiele, H, Tizard, J, Weksberg, R, Lupski, JR, Stockton, DW: Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. *Nat Genet*, 30: 215-220, 2002.

22. Kaplan, JM, Kim, SH, North, KN, Rennke, H, Correia, LA, Tong, HQ, Mathis, BJ, Rodriguez-Perez, JC, Allen, PG, Beggs, AH, Pollak, MR: Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. *Nat Genet*, 24: 251-256, 2000.
23. Akilesh, S, Suleiman, H, Yu, H, Stander, MC, Lavin, P, Gbadegesin, R, Antignac, C, Pollak, M, Kopp, JB, Winn, MP, Shaw, AS: Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. *The Journal of clinical investigation*, 121: 4127-4137, 2011.
24. Brown, EJ, Schlondorff, JS, Becker, DJ, Tsukaguchi, H, Tonna, SJ, Uscinski, AL, Higgs, HN, Henderson, JM, Pollak, MR: Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. *Nat Genet*, 42: 72-76, 2010.
25. Dreyer, SD, Zhou, G, Baldini, A, Winterpacht, A, Zabel, B, Cole, W, Johnson, RL, Lee, B: Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. *Nat Genet*, 19: 47-50, 1998.
26. Winn, MP, Conlon, PJ, Lynn, KL, Farrington, MK, Creazzo, T, Hawkins, AF, Daskalakis, N, Kwan, SY, Ebersviller, S, Burchette, JL, Pericak-Vance, MA, Howell, DN, Vance, JM, Rosenberg, PB: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. *Science*, 308: 1801-1804, 2005.
27. Jeanpierre, C, Denamur, E, Henry, I, Cabanis, MO, Luce, S, Cecille, A, Elion, J, Peuchmaur, M, Loirat, C, Niaudet, P, Gubler, MC, Junien, C: Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. *American journal of human genetics*, 62: 824-833, 1998.
28. Tikhomirov, E, Averyanova, N, Bayazutdinova, G, Voznesenskaya, T, Tsygin, A: Novel human pathological mutations. Gene symbol: NPHS2. Disease: steroid-resistant nephrotic syndrome. *Human genetics*, 122: 549, 2007.
29. Weber, S, Gribouval, O, Esquivel, EL, Moriniere, V, Tete, MJ, Legendre, C, Niaudet, P, Antignac, C: NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. *Kidney international*, 66: 571-579, 2004.
30. Al-Hamed, MH, Al-Sabban, E, Al-Mojalli, H, Al-Harbi, N, Faqeih, E, Al Shaya, H, Alhasan, K, Al-Hissi, S, Rajab, M, Edwards, N, Al-Abbad, A, Al-Hassoun, I, Sayer, JA, Meyer, BF: A molecular genetic analysis of childhood nephrotic syndrome in a cohort of Saudi Arabian families. *J Hum Genet*, 58: 480-489, 2013.
31. Tonna, SJ, Needham, A, Polu, K, Uscinski, A, Appel, GB, Falk, RJ, Katz, A, Al-Waheed, S, Kaplan, BS, Jerums, G, Savige, J, Harmon, J, Zhang, K, Curhan, GC, Pollak, MR: NPHS2 variation in focal and segmental glomerulosclerosis. *BMC Nephrol*, 9: 13, 2008.
32. Caridi, G, Bertelli, R, Carrea, A, Di Duca, M, Catarsi, P, Artero, M, Carraro, M, Zennaro, C, Candiano, G, Musante, L, Seri, M, Ginevri, F, Perfumo, F, Ghiggeri, GM: Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. *Journal of the American Society of Nephrology : JASN*, 12: 2742-2746, 2001.
33. Tsukaguchi, H, Sudhakar, A, Le, TC, Nguyen, T, Yao, J, Schwimmer, JA, Schachter, AD, Poch, E, Abreu, PF, Appel, GB, Pereira, AB, Kalluri, R, Pollak, MR: NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. *The Journal of clinical investigation*, 110: 1659-1666, 2002.
34. Kerti, A, Csohany, R, Wagner, L, Javorszky, E, Maka, E, Tory, K: NPHS2 homozygous p.R229Q variant: potential modifier instead of causal effect in focal segmental glomerulosclerosis. *Pediatric nephrology*, 28: 2061-2064, 2013.
35. Karle, SM, Uetz, B, Ronner, V, Glaeser, L, Hildebrandt, F, Fuchshuber, A: Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. *Journal of the American Society of Nephrology : JASN*, 13: 388-393, 2002.
36. Carrasco-Miranda, JS, Garcia-Alvarez, R, Sotelo-Mundo, RR, Valenzuela, O, Islas-Osuna, MA, Sotelo-Cruz, N: Mutations in NPHS2 (podocin) in Mexican children with nephrotic syndrome who respond to standard steroid treatment. *Genet Mol Res*, 12: 2102-2107, 2013.
37. Lipska, BS, Iatropoulos, P, Maranta, R, Caridi, G, Ozaltin, F, Anarat, A, Balat, A, Gellermann, J, Trautmann, A, Erdogan, O, Saeed, B, Emre, S, Bogdanovic, R, Azocar, M, Balasz-Chmielewska, I, Benetti, E, Caliskan, S, Mir, S, Melk, A, Ertan, P, Baskin, E, Jardim, H, Davitaia, T, Wasilewska, A, Drozdz, D, Szczepanska, M, Jankauskiene, A, Higuita, LM, Ardissino, G, Ozkaya, O, Kuzma-Mroczkowska, E, Soylemezoglu, O, Ranchin, B, Medynska, A, Tkaczyk, M, Peco-Antic, A, Akil, I, Jarmolinski, T, Firszt-Adamczyk, A, Dusek, J, Simonetti, GD, Gok, F,

- Gheissari, A, Emma, F, Krmar, RT, Fischbach, M, Printza, N, Simkova, E, Mele, C, Ghiggeri, GM, Schaefer, F: Genetic screening in adolescents with steroid-resistant nephrotic syndrome. *Kidney international*, 84: 206-213, 2013.
38. Ruf, RG, Lichtenberger, A, Karle, SM, Haas, JP, Anacleto, FE, Schultheiss, M, Zalewski, I, Imm, A, Ruf, EM, Mucha, B, Bagga, A, Neuhaus, T, Fuchshuber, A, Bakkaloglu, A, Hildebrandt, F: Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. *Journal of the American Society of Nephrology : JASN*, 15: 722-732, 2004.
39. Machuca, E, Benoit, G, Nevo, F, Tete, MJ, Gribouval, O, Pawtowski, A, Brandstrom, P, Loirat, C, Niaudet, P, Gubler, MC, Antignac, C: Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome. *Journal of the American Society of Nephrology : JASN*, 21: 1209-1217, 2010.
40. Single gene disorders. *Genomic Med*, 2: 241-252, 2008.
41. Hinkes, BG, Mucha, B, Vlangos, CN, Gbadegesin, R, Liu, J, Hasselbacher, K, Hangan, D, Ozaltin, F, Zenker, M, Hildebrandt, F: Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). *Pediatrics*, 119: e907-919, 2007.
42. Sako, M, Nakanishi, K, Obama, M, Yata, N, Hoshii, S, Takahashi, S, Wada, N, Takahashi, Y, Kaku, Y, Satomura, K, Ikeda, M, Honda, M, Iijima, K, Yoshikawa, N: Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome. *Kidney international*, 67: 1248-1255, 2005.
43. Philippe, A, Nevo, F, Esquivel, EL, Reklaityte, D, Gribouval, O, Tete, MJ, Loirat, C, Dantal, J, Fischbach, M, Pouteil-Noble, C, Decramer, S, Hoehne, M, Benzing, T, Charbit, M, Niaudet, P, Antignac, C: Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. *Journal of the American Society of Nephrology : JASN*, 19: 1871-1878, 2008.
44. Beltcheva, O, Martin, P, Lenkkeri, U, Tryggvason, K: Mutation spectrum in the nephrin gene (NPHS1) in congenital nephrotic syndrome. *Hum Mutat*, 17: 368-373, 2001.
45. Schoeb, DS, Chernin, G, Heeringa, SF, Matejas, V, Held, S, Vega-Warner, V, Bockenhauer, D, Vlangos, CN, Moorani, KN, Neuhaus, TJ, Kari, JA, MacDonald, J, Saisawat, P, Ashraf, S, Ovunc, B, Zenker, M, Hildebrandt, F: Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS). *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 25: 2970-2976, 2010.
46. Lenkkeri, U, Mannikko, M, McCready, P, Lamerdin, J, Gribouval, O, Niaudet, PM, Antignac, CK, Kashtan, CE, Homberg, C, Olsen, A, Kestila, M, Tryggvason, K: Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. *American journal of human genetics*, 64: 51-61, 1999.
47. Koziell, A, Grech, V, Hussain, S, Lee, G, Lenkkeri, U, Tryggvason, K, Scambler, P: Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. *Human molecular genetics*, 11: 379-388, 2002.
48. Heeringa, SF, Vlangos, CN, Chernin, G, Hinkes, B, Gbadegesin, R, Liu, J, Hoskins, BE, Ozaltin, F, Hildebrandt, F: Thirteen novel NPHS1 mutations in a large cohort of children with congenital nephrotic syndrome. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 23: 3527-3533, 2008.
49. Ulinski, T, Aoun, B, Toubiana, J, Vitkevic, R, Bensman, A, Donadieu, J: Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. *Blood*, 113: 4820-4821, 2009.
50. Shi, Y, Ding, J, Liu, JC, Wang, H, Bu, DF: [NPHS1 mutations in a Chinese family with congenital nephrotic syndrome]. *Zhonghua Er Ke Za Zhi*, 43: 805-809, 2005.
51. Santin, S, Garcia-Maset, R, Ruiz, P, Gimenez, I, Zamora, I, Pena, A, Madrid, A, Camacho, JA, Fraga, G, Sanchez-Moreno, A, Cobo, MA, Bernis, C, Ortiz, A, de Pablos, AL, Pintos, G, Justa, ML, Hidalgo-Barquero, E, Fernandez-Llama, P, Ballarin, J, Ars, E, Torra, R: Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. *Kidney international*, 76: 1268-1276, 2009.

52. Caridi, G, Gigante, M, Ravani, P, Trivelli, A, Barbano, G, Scolari, F, Dagnino, M, Murer, L, Murtas, C, Edefonti, A, Allegri, L, Amore, A, Coppo, R, Emma, F, De Palo, T, Penza, R, Gesualdo, L, Ghiggeri, GM: Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. *Clinical journal of the American Society of Nephrology : CJASN*, 4: 1065-1072, 2009.
53. Gigante, M, Greco, P, Defazio, V, Lucci, M, Margaglione, M, Gesualdo, L, Iolascon, A: Congenital nephrotic syndrome of Finnish type: detection of new nephrin mutations and prenatal diagnosis in an Italian family. *Prenat Diagn*, 25: 407-410, 2005.
54. Schultheiss, M, Ruf, RG, Mucha, BE, Wiggins, R, Fuchshuber, A, Lichtenberger, A, Hildebrandt, F: No evidence for genotype/phenotype correlation in NPHS1 and NPHS2 mutations. *Pediatric nephrology*, 19: 1340-1348, 2004.
55. Buscher, AK, Kranz, B, Buscher, R, Hildebrandt, F, Dworniczak, B, Pennekamp, P, Kuwertz-Broking, E, Wingen, AM, John, U, Kemper, M, Monnens, L, Hoyer, PF, Weber, S, Konrad, M: Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. *Clinical journal of the American Society of Nephrology : CJASN*, 5: 2075-2084, 2010.
56. Boyer, O, Benoit, G, Gribouval, O, Nevo, F, Pawtowski, A, Bilge, I, Bircan, Z, Deschenes, G, Guay-Woodford, LM, Hall, M, Macher, MA, Soulami, K, Stefanidis, CJ, Weiss, R, Loirat, C, Gubler, MC, Antignac, C: Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome. *J Med Genet*, 47: 445-452, 2010.
57. Ismaili, K, Pawtowski, A, Boyer, O, Wissing, KM, Janssen, F, Hall, M: Genetic forms of nephrotic syndrome: a single-center experience in Brussels. *Pediatr Nephrol*, 24: 287-294, 2009.
58. Lucke, T, Billing, H, Sloan, EA, Boerkel, CF, Franke, D, Zimmering, M, Ehrich, JH, Das, AM: Schimke-immuno-osseous dysplasia: new mutation with weak genotype-phenotype correlation in siblings. *Am J Med Genet A*, 135: 202-205, 2005.
59. Clewing, JM, Fryssira, H, Goodman, D, Smithson, SF, Sloan, EA, Lou, S, Huang, Y, Choi, K, Lucke, T, Alpay, H, Andre, JL, Asakura, Y, Biebuyck-Gouge, N, Bogdanovic, R, Bonneau, D, Cancrini, C, Cochat, P, Cockfield, S, Collard, L, Cordeiro, I, Cormier-Daire, V, Cransberg, K, Cutka, K, Deschenes, G, Ehrich, JH, Frund, S, Georgaki, H, Guillen-Navarro, E, Hinkelmann, B, Kanariou, M, Kasap, B, Kilic, SS, Lama, G, Lamfers, P, Loirat, C, Majore, S, Milford, D, Morin, D, Ozdemir, N, Pontz, BF, Proesmans, W, Psoni, S, Reichenbach, H, Reif, S, Rusu, C, Saraiva, JM, Sakallioglu, O, Schmidt, B, Shoemaker, L, Sigaudy, S, Smith, G, Sotsiou, F, Stajic, N, Stein, A, Stray-Pedersen, A, Taha, D, Taque, S, Tizard, J, Tsimaratos, M, Wong, NA, Boerkel, CF: Schimke immunoosseous dysplasia: suggestions of genetic diversity. *Human mutation*, 28: 273-283, 2007.
60. Bredrup, C, Matejas, V, Barrow, M, Blahova, K, Bockenhauer, D, Fowler, DJ, Gregson, RM, Maruniak-Chudek, I, Medeira, A, Mendonca, EL, Kagan, M, Koenig, J, Krastel, H, Kroes, HY, Saggar, A, Sawyer, T, Schittkowski, M, Swietlinski, J, Thompson, D, VanDeVoorde, RG, Wittebol-Post, D, Woodruff, G, Zurowska, A, Hennekam, RC, Zenker, M, Russell-Eggitt, I: Ophthalmological aspects of Pierson syndrome. *Am J Ophthalmol*, 146: 602-611, 2008.
61. Motazacker, MM, Peter, J, Treskes, M, Shoulders, CC, Kuivenhoven, JA, Hovingh, GK: Evidence of a polygenic origin of extreme high-density lipoprotein cholesterol levels. *Arterioscler Thromb Vasc Biol*, 33: 1521-1528, 2013.
62. Jung, S, Kang, ES, Ki, CS, Kim, DW, Paik, KH, Chang, YS: Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome. *Journal of clinical apheresis*, 26: 162-165, 2011.
63. Schultheiss, M, Ruf, RG, Mucha, BE, Wiggins, R, Fuchshuber, A, Lichtenberger, A, Hildebrandt, F: No evidence for genotype/phenotype correlation in NPHS1 and NPHS2 mutations. *Pediatr Nephrol*, 19: 1340-1348, 2004.
64. Ovunc, B, Ashraf, S, Vega-Warner, V, Bockenhauer, D, Elshakhs, NA, Joseph, M, Hildebrandt, F: Mutation analysis of NPHS1 in a worldwide cohort of congenital nephrotic syndrome patients. *Nephron Clinical practice*, 120: c139-146, 2012.
65. Lovric, S, Fang, H, Vega-Warner, V, Sadowski, CE, Gee, HY, Halbritter, J, Ashraf, S, Saisawat, P, Soliman, NA, Kari, JA, Otto, EA, Hildebrandt, F: Rapid Detection of Monogenic Causes of Childhood-Onset Steroid-Resistant Nephrotic Syndrome. *Clin J Am Soc Nephrol*, 2014.

66. Hinkes, B, Vlangos, C, Heeringa, S, Mucha, B, Gbadegesin, R, Liu, J, Hasselbacher, K, Ozaltin, F, Hildebrandt, F: Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome. *Journal of the American Society of Nephrology : JASN*, 19: 365-371, 2008.
67. Ruf, RG, Schultheiss, M, Lichtenberger, A, Karle, SM, Zalewski, I, Mucha, B, Everding, AS, Neuhaus, T, Patzer, L, Plank, C, Haas, JP, Ozaltin, F, Imm, A, Fuchshuber, A, Bakkaloglu, A, Hildebrandt, F: Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. *Kidney international*, 66: 564-570, 2004.
68. Mucha, B, Ozaltin, F, Hinkes, BG, Hasselbacher, K, Ruf, RG, Schultheiss, M, Hangan, D, Hoskins, BE, Everding, AS, Bogdanovic, R, Seeman, T, Hoppe, B, Hildebrandt, F: Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. *Pediatr Res*, 59: 325-331, 2006.
69. Chernin, G, Vega-Warner, V, Schoeb, DS, Heeringa, SF, Ovunc, B, Saisawat, P, Cleper, R, Ozaltin, F, Hildebrandt, F: Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations. *Clin J Am Soc Nephrol*, 5: 1655-1662, 2010.
70. Gbadegesin, R, Hinkes, BG, Hoskins, BE, Vlangos, CN, Heeringa, SF, Liu, J, Loirat, C, Ozaltin, F, Hashmi, S, Ulmer, F, Cleper, R, Ettenger, R, Antignac, C, Wiggins, RC, Zenker, M, Hildebrandt, F: Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 23: 1291-1297, 2008.
71. Hasselbacher, K, Wiggins, RC, Matejas, V, Hinkes, BG, Mucha, B, Hoskins, BE, Ozaltin, F, Nurnberg, G, Becker, C, Hangan, D, Pohl, M, Kuwertz-Broking, E, Griebel, M, Schumacher, V, Royer-Pokora, B, Bakkaloglu, A, Nurnberg, P, Zenker, M, Hildebrandt, F: Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. *Kidney international*, 70: 1008-1012, 2006.
72. Kagan, M, Cohen, AH, Matejas, V, Vlangos, C, Zenker, M: A milder variant of Pierson syndrome. *Pediatr Nephrol*, 23: 323-327, 2008.
73. Lehnhardt, A, Lama, A, Amann, K, Matejas, V, Zenker, M, Kemper, MJ: Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR. *Pediatr Nephrol*, 27: 865-868, 2012.
74. Heeringa, SF, Moller, CC, Du, J, Yue, L, Hinkes, B, Chernin, G, Vlangos, CN, Hoyer, PF, Reiser, J, Hildebrandt, F: A novel TRPC6 mutation that causes childhood FSGS. *PLoS One*, 4: e7771, 2009.
75. Gee, HY, Saisawat, P, Ashraf, S, Hurd, TW, Vega-Warner, V, Fang, H, Beck, BB, Gribouval, O, Zhou, W, Diaz, KA, Natarajan, S, Wiggins, RC, Lovric, S, Chernin, G, Schoeb, DS, Ovunc, B, Frishberg, Y, Soliman, NA, Fathy, HM, Goebel, H, Hoefele, J, Weber, LT, Innis, JW, Faul, C, Han, Z, Washburn, J, Antignac, C, Levy, S, Otto, EA, Hildebrandt, F: ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. *The Journal of clinical investigation*, 123: 3243-3253, 2013.
76. Clarkson, PA, Davies, HR, Williams, DM, Chaudhary, R, Hughes, IA, Patterson, MN: Mutational screening of the Wilms's tumour gene, WT1, in males with genital abnormalities. *J Med Genet*, 30: 767-772, 1993.
77. Pelletier, J, Bruening, W, Kashtan, CE, Mauer, SM, Manivel, JC, Striegel, JE, Houghton, DC, Junien, C, Habib, R, Fouser, L, et al.: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. *Cell*, 67: 437-447, 1991.
78. Santin, S, Bullich, G, Tazon-Vega, B, Garcia-Maset, R, Gimenez, I, Silva, I, Ruiz, P, Ballarin, J, Torra, R, Ars, E: Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. *Clin J Am Soc Nephrol*, 6: 1139-1148, 2011.
79. Kikuchi, H, Takata, A, Akasaka, Y, Fukuzawa, R, Yoneyama, H, Kurosawa, Y, Honda, M, Kamiyama, Y, Hata, J: Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier syndrome? *J Med Genet*, 35: 45-48, 1998.
80. Wagner, N, Wagner, KD, Afanetti, M, Nevo, F, Antignac, C, Michiels, JF, Schedl, A, Berard, E: A novel Wilms' tumor 1 gene mutation in a child with severe renal dysfunction and persistent renal blastema. *Pediatric nephrology*, 23: 1445-1453, 2008.
81. Barbaux, S, Niaudet, P, Gubler, MC, Grunfeld, JP, Jaubert, F, Kuttenn, F, Fekete, CN, Souleyreau-Therville, N, Thibaud, E, Fellous, M, McElreavey, K: Donor splice-site mutations in WT1 are responsible for Frasier syndrome. *Nat Genet*, 17: 467-470, 1997.

82. Li, J, Ding, J, Zhao, D, Yu, Z, Fan, Q, Chen, Y, Zhang, H, Zhong, X, Huang, J, Yao, Y, Xiao, H: WT1 gene mutations in Chinese children with early onset nephrotic syndrome. *Pediatric research*, 68: 155-158, 2010.
83. Reiser, J, Polu, KR, Moller, CC, Kenlan, P, Altintas, MM, Wei, C, Faul, C, Herbert, S, Villegas, I, Avila-Casado, C, McGee, M, Sugimoto, H, Brown, D, Kalluri, R, Mundel, P, Smith, PL, Clapham, DE, Pollak, MR: TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. *Nat Genet*, 37: 739-744, 2005.
84. Gigante, M, Caridi, G, Montemurno, E, Soccio, M, d'Apolito, M, Cerullo, G, Aucella, F, Schirinzi, A, Emma, F, Massella, L, Messina, G, De Palo, T, Ranieri, E, Ghiggeri, GM, Gesualdo, L: TRPC6 mutations in children with steroid-resistant nephrotic syndrome and atypical phenotype. *Clin J Am Soc Nephrol*, 6: 1626-1634, 2011.
85. Boyer, O, Nevo, F, Plaisier, E, Funalot, B, Gribouval, O, Benoit, G, Cong, EH, Arrondel, C, Tete, MJ, Montjean, R, Richard, L, Karras, A, Pouteil-Noble, C, Balafréj, L, Bonnardeaux, A, Canaud, G, Charasse, C, Dantal, J, Deschenes, G, Deteix, P, Dubourg, O, Petiot, P, Pouthier, D, Leguern, E, Guiochon-Mantel, A, Broutin, I, Gubler, MC, Saunier, S, Ronco, P, Vallat, JM, Alonso, MA, Antignac, C, Mollet, G: INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. *The New England journal of medicine*, 365: 2377-2388, 2011.
86. Barua, M, Brown, EJ, Charoonratana, VT, Genovese, G, Sun, H, Pollak, MR: Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. *Kidney international*, 83: 316-322, 2013.
87. Isojima, T, Harita, Y, Furuyama, M, Sugawara, N, Ishizuka, K, Horita, S, Kajihara, Y, Miura, K, Igarashi, T, Hattori, M, Kitanaka, S: LMX1B mutation with residual transcriptional activity as a cause of isolated glomerulopathy. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 29: 81-88, 2014.